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Abstract
ADVANCEMENT OF A 3D COMPUTATIONAL PHANTOM AND ITS AGE SCALING
METHODOLOGIES FOR RETROSPECTIVE DOSE
RECONSTRUCTION STUDIES

Aashish Chandra Gupta, B.S.
Advisory Professor: Rebecca M. Howell, Ph.D.

We have used a 3D age-scalable computational phantom for over two decades for
retrospective dose reconstruction studies of childhood cancer survivors (CCS) treated with 2D
historic radiotherapy (RT). However, our phantom and its age scaling functions (ASF) must be
updated so that it can be used in studies that include survivors treated with contemporary
RT. We aimed to implement our phantom and its age scaling functions in DICOM format and
determine the feasibility of applying our ASFs to accurately scale the whole-body CT-based
anatomies.
In the implementation study, we developed Python scripts that model the phantom
and ASFs in a treatment planning system (TPS). We validated the implementation by
comparing several geometric and anthropometric parameters with reference datasets. We
then conducted a dosimetric analysis to determine the accuracy of dose calculation using our
phantom. In the feasibility study, we downscaled various computed tomography (CT)-based
vi

phantoms from the University of Florida/National Cancer Institute (UF/NCI) phantom library
to arbitrary ages. We quantified the geometric accuracy of scaling by comparing several
overlaps, distance, and anthropometric parameters of the scaled phantom with reference
datasets. We also assessed the dosimetric impact of ASFs by quantifying the difference in
dose from standard Wilms’ tumor RT plan simulated on exact age-scaled and nearest agematched phantom while using the same field size and anatomical landmark dependent field
size in two different scenarios.
This study showed that phantoms were implemented in DICOM format within 3% of
points/volume of our original phantoms. The heights and dosimetric accuracy were within 7%
of ground-truth values. In the feasibility study, overlap metrics showed “good” agreement for
most cases except pancreas and kidneys. The maximum displacement of 4.1cm was obtained
in the scaled liver. In both implementation and feasibility studies, organ masses were smaller
than reference masses in general. A difference of 6% and 1.3Gy was obtained for percent
volume ≥ 15Gy (V15) and mean dose, respectively, across two phantom categories when the
same field size was used. Both metrics were significantly different (p<0.05) for partially inbeam organs when field size varied. Overall, our results show that phantom and ASFs can be
accurately used in TPS for modern RT studies, and our ASFs can accurately scale whole-body
CT-based anatomy.
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Chapter 1: Introduction
1. Background to the Problem
The advancements of radiation therapy (RT) treatment techniques have increased the
survival rate of cancer patients over the last few decades, however, RT modalities are
associated with dose to non-target organs/organs at risk (OAR) at the same time (Kry et al
2017). The dose to OARs depends on the proximity of the organ to the target volume. Organs
that are completely in-beam or partially in-beam receive varying degrees of unwanted
radiation, largely depending on their proximity to the target volume. Organs that are entirely
out of beam receive lesser amounts of unwanted radiation due to stray radiation originating
from linac head leakage, collimator scatters, and patient scatters (Kry et al 2017, Xu et al
2008). The dose received by these OARs increases the risk of developing early and late
effects/toxicity in these organs (Kry et al 2017). It has been estimated that 1% of the cancer
survivors will develop RT-related subsequent neoplasm (SNM), which corresponds to
approximately 150,000 patients (De Gonzalez et al 2011). In the case of childhood cancer
survivors (CCS) treated with radiation therapy (RT), the survivors are at higher risk to develop
late effects as they have greater tissue sensitivity to radiation (Kutanzi et al 2016), a longer
life expectancy, and a greater survival rate than an adult (Armstrong et al 2016, Turcotte et al
2017, Gibson et al 2018).
1.1 RT epidemiologic studies
The risk of developing late effects is investigated in radiation epidemiologic studies (also
known as late effects studies) where doses from RT to OARs are correlated with late effects in
1

those organs in long-term cancer survivors. Because late effects occur years and often
decades after treatment, survivor cohorts often include survivors treated in the precomputed tomography era of RT. Thus, organ doses are not available in their historic RT
records and must be reconstructed in retrospect using surrogate anatomy. This is typically
done using established dose reconstruction methods (Stovall et al 2006, Howell et al 2019),
briefly summarized here.
We first begin by abstracting RT treatment plan from the cancer survivor cohort
(N>10,000), and then we reconstruct RT fields on surrogate anatomy to estimate dose to
OARs (Stovall et al 2006, Howell et al 2019). The abstraction usually involves coding of
anthropometric parametric and RT plans of the survivor. If the cohorts include survivors
treated in the pre-CT era, then parameters such as age, height and weight (sporadically
available), sex, date, prescription dose, beam energy, orientation, field size, anatomical
landmarks, and organs proximity to the fields are available (Howell et al 2019). These
parameters are used to reconstruct the dose on the surrogate anatomy. If the cohort
includes survivors treated with contemporary RT such as 3D conformal RT, intensity,
volumetric modulated RT (IMRT and VMAT) and particle therapy, then a survivor CT scan with
an RT plan is available. However, partial CT scans are available in most cases where
information is limited to anatomy near the target volume. Therefore, surrogate anatomy for
missing organs/body regions is combined with a partial CT scan to estimate the organ dose.
Since doses are reconstructed in retrospect in both cases, the success of such studies is
heavily dependent on the accuracy, suitability, and efficacy of dose reconstruction methods
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and the type of surrogate anatomy used in the studies as associated uncertainty could result
in a large error in risk assessments (Xu et al 2008, Vũ Bezin et al 2017).
There are two major approaches that are used to reconstruct organ doses from the stray
radiation: (1) anthropometric phantom approach, (2) computational approaches (Stovall et al
2006, Howell et al 2019, Kry et al 2017, Xu et al 2008). In the anthropometric phantom
approach, organ doses are measured using phantoms such as Alderson RANDO phantoms
which consist of contiguous plastic slabs of tissue equivalent materials for varying the shape
and the size. The dosimeters such as Thermoluminiscents detectors (TLD) are placed at
different distances and depths, and the phantoms are irradiated using treatment parameters
to estimate the dose (Stovall et al 2006). There exist several limitations that preclude its use
in large cohorts of cancer survivors. First of all, the anthropometrics phantoms are limited to
specific ages, and the phantom slabs have limited thickness and number per body region,
limiting the variation in shape. Further, it is not feasible to perform the physical experiments
using phantoms for all survivors in large cohorts. In computational approaches, a treatment
planning system (TPS) can be used to estimate in-beam or partially in-beam organ dose, but
the accuracy decreases as the distance between out-of-field organ and main treatment field
increases (Kry et al 2017). It has been found that TPS exhibits up to 30% error in organ doses
that are 3cm from the field edges (Howell et al 2010b). The Monte Carlo methods are one of
the feasible options in which different treatment scenarios and patient geometrical models
can be simulated. However, the models must be validated with the machines used for
treatment (Kry et al 2017) which is not feasible to conduct for each survivor in large cohorts.
Considering the limitations mentioned above, the most viable option for large cohorts is
3

analytical dose calculation models combined with 3D computational phantoms. The analytical
models consist of mathematical formulation and measurement data for different field sizes,
beam energy, depth, orientation, etc., which are used when RT fields are reconstructed on
computational phantoms to reconstruct dose to OARs (Stovall et al 2006, Howell et al 2019,
Kry et al 2017).
1.2 Computational phantoms
There are different categories of computational phantoms that have the potential for use
in late effects studies. The first and the simplest class is stylized phantoms which is also the
most widely used phantom type for CCS treated in the pre-CT era (Howell et al 2019). Stylized
phantoms consist of simple geometrical shapes that represent organs and body regions (Xu
2014). The geometrical structures are described by quadratic equations, allowing them to be
scaled to match various anthropometric parameters (Kry et al 2017, Zaidi and Tsui 2009, Xu
2014). However, the main limitation of these phantoms is the deviation from realistic and
complex human anatomy, which could introduce uncertainty in organ dose estimation if the
dose reconstruction method relies on the organ shape. The anatomical realism has been
addressed up to an appreciable extent in the next category known as Voxel phantoms. In this
type, the voxels defining organs and body regions are obtained by segmenting patient
CT/MRI scans (Lee et al 2010, Zaidi and Tsui 2009, Xu 2014). Voxels defining a particular
organ are given the same identification numbers. Although voxel phantoms are anatomically
more realistic than stylized phantoms, they cannot be scaled to different heights, ages,
weights, etc., which results in errors up to 150% in some cases when used instead of stylized
phantoms (Kry et al 2017, Lee et al 2006). The most advanced and most realistic category of
4

the phantom is hybrid phantoms which combine anatomical realism of voxel phantoms with
the mathematical surface equations of the stylized phantoms (Bolch et al 2010). There are
several hybrid phantom libraries which include reference size, body-size dependent (height
and weight dependent), patient-specific, and percentile-specific phantoms and can be scaled
to match various anthropometric parameters but the time required to scale each phantom
ranges up to 20 minutes which could result in the longer calculation time for large cohorts.
Another limitation is that phantoms are available at discrete ages (e.g. newborn, 1, 5, 10, 15,
adult) or at discrete heights or discrete weights due to which nearest available age or height
or weight are used when the phantom of exact parameter for survivors is unavailable. The
could result in uncertainty organ dose and risk-assessment studies.
2. MD Anderson Late Effects Group Computational Phantoms and Statement of the Problem
The Radiation Dosimetry Service (RDS) at UT MD Anderson Cancer Center developed a 3D
age-scalable computational phantom over three decades ago, which has been used in more
than 120 studies for retrospective dose reconstruction of CCS treated with 2D RT plans
(Howell et al 2019). This phantom was modeled initially in FORTRAN and can be scaled to any
arbitrary age using non-uniform body region-specific 3D age-scaling functions (ASFs). The
phantom consists of 5 rectangular cuboids representing the head, neck, trunk, legs, arms,
body regions, and over 20 organs. Each body region and organ is represented by 3D points,
and doses are predicted by calculating the dose to individual points using several
reconstruction methods as described by Stovall et al (2006) and Howell et al (2019). The
availability of robust and fast age-scaling methodologies makes this phantom suitable for the
dose reconstruction studies of large retrospective cohorts.
5

The modern cohorts of CCS are treated with contemporary RT modalities such as 3D CRT,
IMRT, and VMAT, where survivor's treatment plans are present in Digital Imaging and
Communication in Medicine (DICOM) Standard CT images. In most cases, the survivors have
partial CT scans that only span the anatomy in the proximity of the target volume. To
estimate dose to organs that are not present in the CT image, one must calculate dose
retrospectively using the alternative dose reconstruction methods as TPS calculated doses
are inaccurate for out-of-field organs. Furthermore, in some longitudinal studies, whole-body
CT scans of survivors could be available, which will need to be downscaled and fused with a
partial CT scan of the survivor at different timepoints. Our dose reconstruction method and
computational infrastructure can accurately estimate dose in the previously mentioned
cases, provided that the computational phantom and its ASFs are accurately implemented in
the DICOM format.
3. Project Objective
The overall objective of this project was to make our phantom and its ASFs compatible
with survivors treated with modern RT and determine the feasibility and accuracy of scaling
whole-body CT-based anatomies using our ASFs. Specifically, we first aimed to implement
and validate our phantom and its ASFs in DICOM format. Secondly, we implemented and
validated our ASFs to determine the feasibility of scaling whole-body CT-based anatomy to
any arbitrary age. The implementation mentioned above, and validation will allow us to use
our computational phantoms for cohorts treated with contemporary RT and the ASFs to scale
any other whole-body CT-based anatomy, allowing us to use exact age-scaled phantoms in
late-effects studies.
6

4. Organization of the Thesis
In Chapter 2 of the thesis, the details about the hypothesis, specific aims, and the projects
within each aim are presented. In chapter 3, the implementation and validation of our
computational phantom in the DICOM format are discussed. In chapter 4, the feasibility of
scaling whole-body CT-based anatomy is discussed. In chapter 5, the general overview and
future direction of the project are presented. In appendix A, the mathematical theory of
scaling our computational phantom to 7.0-year-old is presented. In appendix B, the scaling of
the arbitrary computational phantom using our ASFs through a graphical user interface (GUI)
in the commercial treatment planning system is presented.

7

Chapter 2: Central Hypothesis and Specific Aims
1. Central Hypothesis
The central hypothesis of this thesis is that we can accurately convert our current
phantom and its ASFs to DICOM format (within 3%) in a commercial TPS with the ability to
scale our phantom and any CT based anatomy to any arbitrary age, i.e., infant through adult
such that the phantom height across the age range agrees within 7% of the reference height
data
2. Specific Aim 1: Implementation and Validation in the DICOM Format
Aim: Implement the phantom in DICOM format and establish the geometric accuracy in
modeling of body regions and organs
Hypothesis: The computational phantom can be modeled in DICOM format within ± 3% of
the FORTRAN phantom
Project 1.1: Develop a python script to implement the baseline FORTRAN phantom and its
ASFs in DICOM format within TPS
Project 1.2: Validate the phantoms in DICOM format with FORTRAN phantom and reference
data from Center for Disease Control and Prevention, and International Commission on
Radiological Protection 89 report
Project 1.3: Investigate the feasibility of using phantom in DICOM format for dose calculation
in commercial TPS and validate the organ dose with in-house dose calculation software
Specific Aim 1 is fully addressed in chapter 3: Development of an age-scalable 3D
computational phantom in the DICOM format
8

3. Specific Aim 2: Feasibility of Scaling CT-Based Anatomy to Arbitrary Ages
Aim: Apply ASFs to scale the whole-body CT based anatomy to any arbitrary ages and
validate scaling with ground-truth anatomy and reference data
Hypothesis: The ASFs can be used to scale whole-body CT-based anatomy to any arbitrary
ages age within 7% of the CDC reported reference height. The Dice similarity coefficient (DSC)
and mean distance agreement (MDA) of the scaled and ground-truth anatomy are within ≥
70% and within 5cm, respectively.
Project 2.1: Develop a python script to classify the whole-body CT based anatomy to head,
neck, trunk, and leg body regions
Project 2.2: Apply the ASFs to scale whole-body CT based anatomy to any arbitrary age
Project 2.3: Validate the scaled anatomy with ground-truth anatomy and reference data from
CDC and ICRP 89
Project 2.4: Apply ASFs to conduct a dose study to determine the difference in organ doses of
exact age-scaled versus nearest age-matched phantoms
Specific Aim 2 is fully addressed in chapter 4: Scaling of whole-body computed tomographybased anatomy to any age.
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Chapter 3: Development of an Age-Scalable 3D Computational
Phantom in the DICOM Format
This chapter is based on the following peer-reviewed publication:
A.C. Gupta, S. Shrestha, C.A. Owens, S.A. Smith, Y. Qiao, R.E. Weathers., P.A. Balter, S.F. Kry,
and R.M. Howell, “Development of an age-scalable 3D computational phantom in DICOM
standard for late effects studies of childhood cancer survivors,” Biomedical Physics and
Engineering Express. Volume 6, Issue 6, pages 1-15. © IOP Publishing Ltd.
This work is licensed under a Creative Commons Attribution 4.0 license. It is attributed to
Aashish C. Gupta, Suman Shrestha, Constance A. Owens, Susan A. Smith, Ying Qiao, Rita E.
Weathers., Peter A. Balter, Stephen F. Kry, and Rebecca M. Howell, and the original version
can be found here.
This chapter describes the results of Specific Aim 1: Implement the phantom in
DICOM format and establish the geometric accuracy in modeling of body regions and organs
1. Introduction
As mentioned in chapter 1, cancer survivors whose treatment included radiation therapy
(RT) are at risk for developing RT-related late effects (≥5 years after diagnosis) (Travis et al
2011). Survivors of childhood cancer are at particularly high risk because of high survival rates
(>84%) and long-life expectancy (Armstrong et al 2016, Turcotte et al 2017, Gibson et al
2018, Howlader et al 2019). Retrospective epidemiologic studies of cancer survivor cohorts
investigate the relationship between RT dose to specific organs or body regions and the risk
of subsequent late effects (Travis et al 2011). Such studies typically use computational
10

phantoms to retrospectively reconstruct doses throughout patients' bodies (Lee et al 2010,
Travis et al 2011, Xie and Zaidi 2014, Howell et al 2019) by recomputing the radiation field
doses on a phantom. For cohorts that include survivors of childhood cancers, phantoms
should be scalable to the age or size of the patient at the time of RT.
For over two decades (>120 studies), the MD Anderson Late Effects Group has used an
age-scalable computational phantom to reconstruct dose to organs throughout the body for
large cohorts of childhood cancer survivors treated with conventional two-dimensional (2D)
historic RT (Howell et al 2019). This phantom is currently coded in the FORTRAN 95
programming language and can only be used with co-planar beam geometries, which were
standard in 2D planning. Furthermore, its current format does not support instantaneous or
three-dimensional (3D) visualization. These limitations were acceptable for previous studies
with cohorts treated with historic 2D RT. However, cancer survivors now include individuals
treated with contemporary RT, e.g., 3D conformal RT, intensity- and volumetric-modulated
RT, and particle therapy. For these individuals, complex treatment plans were designed using
patients' computed tomography (CT) images within commercial treatment planning systems
(TPS). Unlike in the 2D treatment planning era, dose to organs near the target volume are
readily calculable as part of the treatment plans and therefore, will not need to be
retrospectively recalculated. However, doses to distant organs will still need to be
retrospectively reconstructed on computational phantoms, because CT images used for
treatment planning may not be available for epidemiologic studies, and even if they are, the
CT data will be limited to anatomy near the target volume and will not include distant
structures that are typically of interest in such epidemiologic studies.
11

For retrospective whole-body dose reconstructions, the 'missing' anatomy could be
supplemented by registering a patient's planning CT(s) with a computational phantom scaled
to the age at RT. The MD Anderson Late Effects Group computational phantom is well suited
for this purpose because (1) it is the most widely used phantom for late effects studies of
historic RT and using this same phantom for studies involving contemporary RT will facilitate
direct comparison of results between historic and modern studies; and (2) it can be uniquely
scaled to any arbitrary age or height whereas other computational phantoms are limited to
specific selected ages. However, the MD Anderson Late Effects Group computational
phantom is programmed in FORTRAN language, which is not compatible for registration with
patients' Digital Imaging and Communications in Medicine (DICOM) format CT images in
commercial TPSs. Therefore, the primary objective of this study was to adapt the current
model of our age-scalable computational phantom from the FORTRAN language to DICOM
format for use within any commercial TPS, thereby facilitating epidemiologic studies of
contemporary radiotherapy. Additionally, we report a detailed description of our age-based
scaling functions, information that was not reported in our previous publications. Note that
hereafter, we use phantom, FORTRAN, and DICOM for computational phantom, FORTRAN
language, and DICOM format, respectively.
2. Methods
2.1 Phantom modeled in FORTRAN language (baseline phantom description)
The MD Anderson Late Effects Group phantom was previously described by Howell et al
(2019) and Stovall et al (2006). The phantom was built by bounding the body regions, i.e.,
head, neck, trunk, arms, and legs, of a generic gender-neutral adult skeleton (age = 18 years)
12

by cuboids, which were then fit to a 3D grid of evenly spaced points (Figure 1). Each cuboid is
defined by its eight corner points obtained from its fit to the 3D grid. Various organs are
defined within the phantom's body regions as grids of points (Howell et al 2019).

Figure 1: Diagrams of our computational phantom fitted to a 3D grid of points. (a) coronal
view showing +x and –y axes and (b) sagittal view showing –y and –z axes. A skeleton is
13

overlaid on the phantom for anatomic reference. The scalable body regions (head, neck,
trunk, and extremities) are delineated in frontal view.
2.2 Scaling functions
Because this phantom was intended for use in late effects studies of cancer survivors,
including children, whose ages at the time of their RT ranged from infant to adult, it was
necessary to define scaling functions to adapt the generic adult phantom (18 years of age) to
any age. The head, neck, trunk, and extremities of the human body undergo non-uniform
growth from infant to adulthood. For example, at birth the human head makes up
approximately one quarter of the total height, but that proportion decreases to about oneseventh by adulthood (Huelke 1998). This non-uniform growth was quantitatively reported by
the Society of Automotive Engineers based on measurements of 4127 US infants, children
and youths through 18 years old (Snyder et al 1977). As a function of age, using these growth
data, we plotted sizes of the head, neck, trunk, and extremities (legs and arms) in three
dimensions (Figure 2). Then, we calculated the discrete scaling factor, Fdis , by taking the ratio
of the size of a specified body region r in a specified direction d at a given age a to its size in
the generic phantom, equation (1).

Fdis (d, r, a) =

S(d, r, a)
S(d, r, g)

1

where:
d ∈ {Left to right (x), superior to inferior (y), anterior to posterior (z)}
r ∈ {upper head (uh), lower head (lh), neck (n), trunk (tr), arms (ar), legs (lg)}
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a ∈ {0.1 (1 month), 1, 3, 5, 10, 15, 18} and
g is a constant and is defined as age 18 years; the age of the generic phantom
Since equation (1) can only be used for scaling to discrete ages of 0.1 (1 month), 1, 3, 5, 10,
15, and 18 years, to allow scaling between these ages, we created age intervals of [0, 1), [1,
3), [3, 5), [5, 10), [10, 15), and [15, 18) and defined a continuous scaling function, for each age
interval (equation (2)).
Fcont (d, r, a) = Fdis (d, r, a− ) +

a − a−
(F (d, r, a+ ) − Fdis (d, r, a− ))
a+ − a− dis

2

Where a− and a+ are lower and upper age bounds, respectively. Each organ was considered
to follow the same scaling as the body region in which it was located.
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Figure 2: (A)–(E) Growth as a function of age from superior to inferior, left to right, and
anterior to posterior for the head, neck, trunk, arms and legs for ages 1 month, 1, 3, 5, 10, 15,
and 18 (adult) years (Snyder et al 1977, Huelke 1998).
2.3 Transformation functions
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Each body region is represented by eight corner points and each organ is represented by
a grid of points, where each point (P) is a set of three real numbers (coordinates) denoted by
the variables 𝑥, 𝑦, and 𝑧, which represent the coordinates of a point. Once the necessary
scaling factors are obtained using the scaling functions from section 2.2, we can apply these
factors to each body region corner point and each organ point to transform them to various
ages. Additionally, in the 𝑦 and 𝑧 directions, translations are also necessary so that all body
regions remain contiguous and do not overlap as they scale; they are applied as described in
the following paragraphs.
Since the generic phantom is symmetric about the x-axis (Figure 1), the transformed xcoordinate 𝑥𝑡 can be obtained by taking the product of the continuous scaling factor (𝐹𝑐𝑜𝑛𝑡 )
and the x-coordinate (𝑥), equation (3).
𝑥𝑡 = 𝑥 · 𝐹𝑐𝑜𝑛𝑡 (𝑥, 𝑟, 𝑎)

3

Conversely, the generic phantom is asymmetric about the y-axis and starts at the 𝑥 − 𝑧 plane
where 𝑦 = 1 cm (Figure 1). To obtain the transformed y-coordinate (𝑦𝑡 ), we sum the product
of the continuous scaling factor and the length for each body region (𝑙𝑟,𝑦 ) along the y-axis of
the generic phantom, equation (4). The length of each body region along the y-axis is
obtained by taking the difference between the inferior (𝑖𝑏𝑟) and superior (𝑠𝑏𝑟) boundaries of
that body region in the generic phantom, i.e. 𝑦𝑖𝑏𝑟𝑟 , and 𝑦𝑠𝑏𝑟𝑟 , respectively. For the body
region in which the point lies, the length is the difference between the y-coordinate (𝑦) and
the superior boundary of that body region.
r

y − ysbrr , y ∈ r
yt = ∑ lr,y ⋅ Fcont (y, r, a) where lr,y = { y
ibrr − ysbrr , y ∉ r

4

r=uh
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Similarly, the generic phantom is asymmetric about the z-axis and the anterior aspect
of each body region is at a different location in the x-y plane. Thus, to calculate a transformed
z-coordinate (𝑧𝑡 ) first we calculate the difference between the z-coordinate (𝑧) and the
anterior boundary of the body region in the z direction (𝑧𝑎𝑏𝑟𝑟 ). Next, we multiply this
difference by the continuous scaling factor. Lastly, we add a (𝑧𝑠ℎ𝑖𝑓𝑡 ), equation (5).
𝑧𝑡 = (𝑧 − 𝑧𝑎𝑏𝑟 𝑟 ) ⋅ 𝐹𝑐𝑜𝑛𝑡 (𝑧, 𝑟, 𝑎) + 𝑧𝑠ℎ𝑖𝑓𝑡

5

where zshift is described in equation (6) and differs according to the body region,

zshift =

lr=head,z ⋅ Fcont (z, uh, a) − lr,z ⋅ Fcont (z, r, a)
2

6

where lr,z is the length of the body region in the z direction.
2.4 Phantom adaptation from FORTRAN to DICOM
For this study, we used RayStation V8.99 TPS (RaySearch Laboratories, Stockholm)
because this TPS is used in our clinic and allows addition of user-specific customized features
via Python scripting. We developed a script in Python that converts the generic phantom
from FORTRAN to DICOM. The conversion is a 7-step process (Figure 3), which is executed
through a graphical user interface (GUI) scripted within the RayStation TPS.
1. Import Data: The corner points of each body region and the points of 9 different
organs for the generic phantom (age = 18 years) are imported from the FORTRAN
code into RayStation. The organs that were modeled in this study are – Brain (Frontal
Lobes (Right and Left), Temporal Lobe (Right and Left), Parietal Lobe (Right and Left),
Cerebellum, Occipital Lobes, and Inner brain), Heart, Liver, Lungs (Right and Left),
Stomach, Pancreas, Kidneys (Right and Left), and Thyroid Lobes (Right and Left).
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2. Select Phantom Age: The user is then prompted to select the desired age. The user
can select any value from 0.1 (i.e., newborn) to 18 years. Values are specified to the
nearest tenth of a year. We assume growth stops at age 18 and for ages above 18,
phantom is simply scaled to age 18.
3. Transform Coordinates: Equations (1) through (6) are hardcoded into the script. Based
on the phantom age selected in step 2, each point imported from step 1 is
transformed using equations (1) through (6). After this step, each organ and body
region will have been scaled to the appropriate size based on the user-selected age.
4. Reorient Phantom: Since the coordinate systems are defined differently in the
FORTRAN code and RayStation TPS, we apply an additional rigid transformation to
reorient the phantom to the most common RT treatment orientation, which is headfirst supine.
5. Convert Body Regions to DICOM format: Each body region is converted from a
collection of vertices to a region of interest (ROI) using RayStation’s Box ROI
generation tool (through python script).
6. Convert Organs to DICOM format: Each organ is converted from a collection of grid
points to an ROI using convex hull algorithm through python script.
7. Plot Phantom in RayStation: Once each body region and organ are in DICOM format,
each can be plotted in RayStation.
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Figure 3: Flow chart explaining the adaptation of the phantom to DICOM format
Once the phantom has been generated in RayStation, users can export the phantom in
DICOM format. This file can be uploaded into any DICOM-compatible TPS. A sample
calculation of transformation of our generic 'adult' phantom to a 7-year-old phantom is
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illustrated in the appendix A. Note that when we adapted our phantom from the FORTRAN to
DICOM, we made two simplifications to the extremities: (1) the legs were simplified to
consist of only one cuboid volume, as opposed to two separate cuboids and (2) the arm
positions were constrained to a single position parallel to the sagittal plane (i.e. superior to
inferior) as opposed to having variable positions of parallel or perpendicular to the sagittal
plane of the body.
2.5 Validation
For this study, we performed two different validation approaches. For the first approach,
we validated the conversion of our phantom model from FORTRAN to DICOM. To do this, we
compared several geometric parameters between the phantom scaled to ages 1 month, 6
months, 1, 2, 3, 5, 8, 10, 15, and 18 years modeled in FORTRAN and DICOM. For the second
approach, we compared the heights of the DICOM model of our phantom with population
height data from the World Health Organization (WHO) and the Centers for Disease Control
and Prevention (CDC) (Centers for Disease Control and Prevention 2000).
2.5.1 Comparison of FORTRAN phantom with DICOM phantom
The first metric we calculated was the percent difference. This metric was calculated
for all corner points in each spatial dimension of each body region and for the volumes of
each body region between the phantom modeled in FORTRAN and DICOM. For the locations
of the corner points, we calculated this difference in the x-, y-, and z-coordinates individually
for each age-scaled phantom. This analysis was done for the head, neck, and trunk body
regions, which includes the majority of organs of interest for late effects studies. Percent
differences (PD) were calculated as follows:
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PD =

F−D
× 100%
F

7

where F corresponds to the coordinates (or volume) from FORTRAN (ground-truth) and D
corresponds to the coordinates (or volume) from DICOM for the specified body region. The
second metric we calculated was the normalized mean square distance (NMSD). The NMSD
was calculated between the organs (heart, liver, lungs, stomach, and brain) for both
phantoms using the following equation.

2
2
2
√∑N
i (xF − xD ) + (yF − yD ) + (zF − zD )

NMSD =

8

N

where, x, y, and z represent the coordinates of each organ point in the phantoms. The
subscripts F and D represent that the coordinate of the point is from the FORTRAN and
DICOM phantoms, respectively. N is the total number of points in each organ.
The third metric we calculated was the difference in heights between the FORTRAN
and DICOM phantoms. This was calculated to ensure that the total height of the phantom
was preserved when converted from FORTRAN to DICOM.
2.5.2 Comparison of DICOM phantom with WHO/CDC population height data
In order to determine if the heights of our age-scaled phantoms were consistent with the
heights of children across the ages of infant to adolescent, we compared our age-scaled
phantom heights with a reference dataset. Specifically, we compared our age-scaled DICOM
phantoms with the 50th-percentile heights reported by the WHO for ages 1 month, 6
months, and 1 year old and with the averages of the 50th-percentile heights for males and
females reported by the CDC for ages 2, 3, 5, 8, 10, 15, and 18 years.
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2.6 Comparison with reference phantoms organ masses
In FORTRAN format, organs in our phantom were modeled as grids of points, making it
impossible to compare organ volumes or masses with other reference phantoms. In the
updated DICOM format, such comparisons are possible and therefore were performed as
part of this work. Specifically, we compared organ masses of the DICOM phantom with
reference masses from International Commission on Radiological Protection (ICRP) 89 (ICRP
2002) and University of Florida (UF)/National Cancer Institute (NCI) reference hybrid voxel
phantoms for ages 6 days (newborn), 1, 5, 10, 15, and 18 years (Adult) (Lee et al 2010). We
first calculated the organ masses for our DICOM phantoms (scaled to aforementioned ages)
as a product of ICRU 46 reference densities and RayStation voxel-based volumes. The volume
of the organs in our DICOM phantom is independent of sex but the ICRP 89 and UF/NCI
reference phantoms provide sex dependent masses for the 15 years old and adult phantoms.
In those cases, the average of male and female reference organ masses were calculated.
Additionally, for the heart and stomach, the UF/NCI reference phantoms have masses for the
wall and contents of these organs. For kidneys, the masses of the medulla, pelvis and cortex
were reported individually. For heart, stomach and kidneys, we calculated the total mass by
summing the mass of each organ's parts. Lastly, we computed the difference between the
organ masses of the DICOM phantom and of the reference phantoms.
2.7 Dose calculation with DICOM phantom—Wilms' tumor example
To illustrate that our phantom can be used for dose calculations within a commercial TPS,
we designed a treatment plan in RayStation and calculated dose to two organs at risk for our
DICOM format phantom. The treatment plan was designed to be representative of a typical
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RT plan for an individual in the Childhood Cancer Survivor Study (CCSS) cohort. To do this, we
selected a common type of paediatric cancer, Wilms' tumor. We then performed a query of
7451 individuals in the CCSS expanded cohort (Leisenring et al 2009, Robison et al 2009) who
received RT between 1985 and 1999 (data collected under IRB approved protocol and RT
records previously abstracted). We identified 318 individuals diagnosed with Wilms' tumor
who were treated with anterior-to-posterior and posterior-to-anterior (AP/PA) directed
abdominal flank fields. From these 318 treatments, we selected the median treatment field
parameters to simulate a typical (6 MV) right-sided flank field RT plan: [1] age at RT: 3.9 years
(range 0.45–20.9 years), target dose 10.80 Gy (range 1.08–36.72 Gy), [3] superior field
border: diaphragm (N = 203), [4] Inferior border: L5 (N = 139). The right-sided AP/PA
treatment fields are illustrated for a 3.9-year-old phantom in FORTRAN and DICOM formats in
Figure 4. Doses to two organs at risk—the liver and pancreas—were calculated. Specifically,
we calculated the mean dose received by each organ and the percentage of each organ that
received dose ≥ 5 Gy (V5 ). For comparison, we simulated the same treatment for our
FORTRAN format phantom and calculated liver and pancreas doses using our in-house
calculation method.

24

Figure 4: Right-sided AP/PA treatment fields simulated for Wilms' tumor RT plan on a
phantom scaled to 3.9 years in (a) FORTRAN and (b) DICOM formats. The coordinates of the
field isocenters and field borders were the same in both planning systems.
3. Results
3.1 Phantom modeled in DICOM standard
The age-scalable computational phantom modeled in DICOM format is illustrated in
Figure 5, which includes 3D renderings of our phantom generated in RayStation TPS and
scaled to ages 1, 5, 10, 15, and 18 (adult).
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Figure 5: Illustration of TPS generated 3D renderings of age-scaled phantoms modeled in
DICOM. Selected organs (brain, lungs, heart, liver, and stomach) were also rendered for each
scaled phantom.

3.2 Comparison between phantom modeled in FORTRAN and DICOM
A histogram illustrating distribution and range of error in reproducing correct locations of
body-region corner points is shown in Figure 6. All observed differences were within 3%, with
0% being most frequently observed. The results of the percent difference calculations in the
volumes of the head, neck, and trunk of the two phantoms are shown in Table 1. For the
volume analysis, we observed all differences within 3%.
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Figure 6: Histogram showing the frequency of percent differences in the corner points of
body regions (excluding legs and arms) of the DICOM phantoms.
Table 1: Percent differences between the volumes of FORTRAN and DICOM phantom body
regions
Age (years)
Body
regions

0.1

0.5

(1 month)

(6 months)

Head

0.8

Neck
Trunk

1

2

3

5

8

10

15

18

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.9

0.1

0.0

0.3

0.3

0.1

0.4

0.0

0.2

0.2

2.8

1.2

1.3

1.2

1.3

1.3

1.3

1.3

1.2

1.2

The normalized mean square distance calculations resulted in strong agreement in the
location of organs across the studied age range. The maximum NMSD was 7.80 ×
10−2 mm for occipital lobe of age 1 month. When we compared the percent differences in
the phantoms' heights modeled in DICOM and FORTRAN, we found accurate agreement
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(difference = 0%) between the phantoms for ages 1, 3, 5, 10, and 15 years and a difference of
0.03% between the phantoms for age 18 years.
3.3 Comparison of DICOM phantom with population height data
Figure 7 shows, for ages 1 month through 20 years, a comparison of the heights of the
age-scaled DICOM phantoms with the averages of the 50th-percentile CDC reported heights
for males and females. The differences were 3.6, 2.1, 0.3, 1.4, 0.6, 1.0, and 0.7% for ages 2, 3,
5, 8, 10, 15, and 18 years, respectively. For 1 month, 6 months, and 1 year, the differences
between the DICOM phantom heights and the WHO 50th-percentile heights were 6.9, 3.1,
and 2.6%, respectively.

Figure 7: Comparison of the heights of the computational phantom modeled in DICOM with
the WHO/CDC heights(Centers for Disease Control and Prevention 2000).
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3.4 Comparison of organ masses of DICOM phantom with ICRP 89, and UF/NCI reference
hybrid phantom data
The masses of nine organs from our DICOM phantom are listed in Table 2. Also reported
in Table 2, are the absolute differences between organ masses in our phantom and those
reported for ICRP 89 and UF/NCI phantoms. The differences are all negative (apart from
newborn brain), i.e., the organ masses in both reference datasets are substantially greater
than the organ masses in our phantom.
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Table 2: Mass (in gram) of DICOM phantom organs and comparison with masses from ICRP 89 and UF/NCI reference hybrid voxel phantom data. In
each case, the difference between DICOM phantom organ mass and ICRP 89 or UF/NCI reference masses were calculated

Organs

Newborn

1 year

DICOM

DICOM ICRP 89

DICOMUF ref.

Heart

12.27

-33.73

Brain

449.40

Liver

5 years

DICOM

DICOM ICRP 89

DICOM UF ref.

-13.68

24.62

-73.38

69.40

128.27

651.56

54.32

-75.68

-75.36

Lungs

41.43

-18.57

Stomach

25.27

-21.73

Pancreas

3.13

Kidneys
Thyroid

10 years

DICOM

DICOM ICRP 89

DICOM UF ref.

18 years (Adult)
DICOM DICOM
ICRP 89

DICOM
- UF ref.

-292.54

135.68

-464.32

-462.82

173.26

-556.74

-555.45

-306.37

-305.84

1083.11

-276.89

-274.11

1153.46

-221.54

-215.17

318.69

-511.31

-510.14

572.21

-727.79

-726.37

738.61

-861.39

-858.70

-152.58

259.93

-240.07

-238.22

460.98

-364.02

-361.87

590.71

-484.29

-481.42

-56.59

133.35

-68.65

-67.44

225.17

-94.83

-94.01

287.68

-97.32

-97.14

-27.72

-27.67

11.56

-48.44

-48.37

20.56

-84.44

-84.19

26.31

-103.69

-103.26

9.21

-100.79

-105.85

16.22

-163.78

-172.78

27.62

-217.38

-229.23

34.17

-258.33

-272.23

0.60

-2.80

-2.80

0.55

-7.35

-7.35

0.61

-11.39

-11.31

0.62

-17.88

-17.82

DICOM

DICOM ICRP 89

DICOMUF ref.

-73.45

42.39

-177.61

-298.44

-298.25

900.89

108.86

-221.14

-220.61

-18.30

84.32

-65.68

-7.05

48.26

-38.74

-2.87

-2.86

5.03

2.76

-22.24

-23.48

0.26

-1.04

-1.03

15 years

DICOM

DICOM ICRP 89

DICOM
–UF ref.

-176.98

76.62

-293.38

-344.11

-343.83

1003.63

181.62

-388.38

-383.20

-65.44

146.05

-153.95

-38.41

75.79

-57.21

-14.97

-14.90

7.28

5.05

-64.95

-68.31

0.44

-1.36

-1.35
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3.5 Results from dose calculation (Wilms’ tumor example)
The V5 and mean dose (Gy) for liver and pancreas calculated with our in-house calculation
system (with FORTRAN phantom) and the RayStation TPS (with DICOM phantom) are
reported in Table 3; percent difference in each case is also reported. The percent differences
between mean doses for liver and pancreas were −4% and 1%, respectively. The percent
differences between V5 values for liver and pancreas were −6%and 7%, respectively.
Table 3: Percent difference between the V5 and mean dose of DICOM and FORTRAN
phantom organs
Organ at
Risk
Liver
Pancreas

V5 (%)
DICOM
91%
72%

FORTRAN
96%
67%

% Diff.
-6%
7%

Mean Dose (Gy)
DICOM
FORTRAN
9.55
9.99
7.57
7.50

% Diff.
-4%
1%

4. Discussion
In this study, we successfully adapted our phantom model from FORTRAN to DICOM,
allowing for importation into any commercial TPS (RayStation, Eclipse, Pinnacle, Monaco,
etc), where it can be used for a variety of dosimetry studies. Analogous to our FORTRAN
phantom, our DICOM phantom can be scaled to any age and can be used to perform
retrospective dose reconstructions for survivors treated with contemporary RT. In such
studies doses to distant organs will need to be retrospectively reconstructed on
computational phantoms because CT images used for treatment planning may not be
available for epidemiologic studies, and even if they are, the CT data will be limited to
anatomy near the target volume and will not include distant structures that are typically of
interest in such epidemiologic studies. For example, for female pediatric brain cancer
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survivors, whose CT scans only included the head and possibly the neck regions, organs of
interest for late effects studies may include the heart, breasts, and ovaries, for which
anatomical information is not present in the CT scan. In such cases, our phantom can be
scaled to any age at RT and co-registered with the patient CT scan, and then doses to other
organs can be reconstructed using the methodologies described in previous studies (Stovall
et al 2006, Howell et al 2019). An important reason for using our phantom in late effect
studies for cohorts treated with contemporary RT is to facilitate comparison with cohorts
treated with historic RT. The dosimetry for RT-related late effects studies in the literature has
been predominantly conducted using the MD Anderson Late Effects Group phantom. Howell
et al (2019) reports more than one hundred late effects studies for which the MD Anderson
Late Effects Group performed dose reconstructions for cohorts with thousands of childhood
cancer survivor studies, e.g. the CCSS, St. Jude Lifetime (Hudson et al 2011, 2017), Adult Life
after Childhood Cancer in Scandinavia (Asdahl et al 2015), and Dutch Childhood Oncology
Group (Teepen et al 2017). Furthermore, other reference phantoms, e.g., UF/NCI, while
anatomically more realistic compared to our phantom, are only available for discrete integer
ages and cannot be scaled to any arbitrary age.
Our validation studies showed that our phantom was correctly adapted from FORTRAN to
DICOM. The histogram analysis of the percent differences between the corner points of head,
neck, and trunk body regions and volumes of the body regions were in good agreement
(within 3%) and the majority (94.4%) of corner points agreed within 1%. The DICOM model of
the phantom consists of organ contours developed from a grid of points that were obtained
after transforming the points of the FORTRAN model of the phantom. The points defining the
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organs were conserved quantitatively between the FORTRAN and DICOM models, with mean
differences being less than 0.1 mm for all organ points. The maximum NMSD obtained was
7.80 × 10−2 𝑚𝑚 for occipital lobe of age 1 month. The heights of our age-scaled phantom
agreed with WHO/CDC data within 7% from infant to adult, with best agreement for ages 5
years and older (<2%).
By modelling our phantom in DICOM, and, in particular, by converting our phantom's
organs from grids of points to contours from which volume (and mass) could be derived, we
were, for the first time, able to compare our phantom's organs masses with those from other
reference phantoms. The results of this analysis demonstrated that the organ masses of our
DICOM phantom are much less than those in both reference phantoms. The differences were
similar in magnitude for comparisons with ICRP 89 and UF/NCI reference phantoms because
the UF/NCI phantoms were adjusted to match ICRP 89 data (Lee et al 2010). It was not
unexpected that our organ masses would differ from more recently developed ICRP 89 and
UF/NCI phantoms because the organs in our FORTRAN phantom, which were the basis of the
organs in the DICOM phantom, were developed from crude sampling of organ points from
cross-sectional anatomical images (Howell et al 2019). While the differences in mass were
large, it is important to underscore that dosimetry conducted with our in-house dose
calculation methodology and FORTRAN phantom did not use organ masses for calculations. In
that system, we calculated doses to the individual points comprising an organ. Then from
those data, the mean organ doses were taken as the mathematical average of the point
doses. Similarly, dose-volume metrics were approximated from percentage of points, e.g.,
the V5 was estimated from the percentage of points with dose ≥5 Gy.
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In this study, we also illustrated that our phantom can be used for dose calculations
within a commercial TPS. This example calculation demonstrated that our DICOM phantom
can be scaled to any age (here 3.9 years), not just the ages illustrated in Figure 1. Also, by
selecting an example case that was typical of the types of calculations for which our in-house
calculation method has been used, we were able to perform the same calculation for both
the FORTRAN and DICOM format phantoms for direct comparison. Notably, we observed
reasonably good agreement (within 7%) between the two calculation methods with the
FORTRAN and DICOM phantoms (Table 3). We attribute the differences between doses to the
more accurate collapsed cone dose calculation algorithm in the RayStation TPS compared to
the very simple 2D method used in our in-house calculation system.
While the DICOM model of our phantom was validated and can be used for dose
calculations in a commercial TPS, the comparison of organ masses for our DICOM phantom
and the organ masses from the reference phantoms revealed that our organs are too small
and highlighted that refinement is necessary. The enhancement that we accomplished in this
study, converting our phantom from FORTRAN to DICOM format, opens new avenues to
achieve this. Namely, we can now register the DICOM model of our phantom with patients'
and other phantoms' (Lee et al 2010) CT images to evaluate the correspondence of organs.
Phantoms enhancements that we are working towards include, redefining organs to be
more anatomically realistic in size and shape and adding substructures to more organs. For
example, the heart, an important organ for RT-related late cardiac disease, was developed
using an anatomy atlas and was modeled as a 55 point grid with no substructures. We can
enhance the shape and size of the heart based on the realistic anatomy and compare the new
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model with models from UF/NCI reference phantoms. The heart model in our phantom could
be further refined by adding substructures and increasing the resolution of points that would
enable calculations of RT doses to specific substructures. These substructure doses could be
used to further enhance dose-response models for RT-related late cardiac disease, which at
present are based on whole-heart doses (Mulrooney et al 2009, Haddy et al 2016, Bates et al
2019). Additionally, other organs in the FORTRAN phantom were designed with low
resolution, e.g., kidneys and pituitary glands have 15 and 1 points, respectively. For these
low-resolution organs, we were not able to create contoured volumes that can structurally
represent the organ in the RayStation TPS. Finally, we are presently working on adding a
colorectal model to our phantom to understand the relationship between dose to the
colon/rectum (and its substructures) and treatment-related colorectal second cancers in
childhood cancer survivors. Existing studies on this topic have not included detailed colorectal
dosimetry (Henderson et al 2012, Nottage et al 2012, Tukenova et al 2012).
5. Conclusion
We successfully adapted our age-scalable computational phantom from the FORTAN
language to DICOM format, which can be imported into any commercial TPS. The modelling
of the phantom in DICOM allows visualization of organs and body regions in three
dimensions, which was not done before. Most importantly, the phantom modeled in DICOM
can be used for late effects studies of cohorts that include survivors treated with
contemporary RT.
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Chapter 4: Scaling of Whole-Body Computed Tomography-Based
Anatomy to Any Age
This chapter is based on the following manuscript which was submitted to Biomedical Physics
& Engineering Express Journal, and it is under review.
A.C. Gupta, C.A. Owens, S. Shrestha, C. Lee, S.A. Smith, R.E. Weathers, T. Netherton, P.A.
Balter, S.F. Kry, D.S. Followill, K.T. Griffin, J.P. Long, G.T. Armstrong, R.M. Howell,
“Implementation and Validation of Non-Uniform Body Region Specific 3D Age-Scaling
Functions to Scale Whole-Body Computed Tomography Anatomy to Any Arbitrary Age for
Late-Effects Studies of Childhood Cancer Survivors,” In Review (2021).
This chapter describes the results of Specific Aim 2: Apply ASFs to scale the wholebody CT based anatomy to any arbitrary ages, and validate scaling with ground-truth
anatomy and reference data.
1. Introduction
In the decades after treatment, childhood cancer survivors are at high risk for developing
treatment-related late effects due to high survival rates for pediatric cancers (> 84%) and
long-life expectancy (Travis and Boice 2012, Armstrong et al. 2016, Gibson et al. 2018).
Radiation epidemiologic studies of childhood cancer survivors seek to establish doseresponse relationships between specific late effects and the dose from radiotherapy (RT) to
the organ in which the late effect occurred (Travis et al 2011). Most childhood cancer
survivor cohorts include survivors treated in the pre-computed tomography (CT) era of RT
and organ doses must, therefore, be estimated by reconstructing RT treatment fields on
36

surrogate anatomy. The most used surrogate anatomy for retrospective RT reconstruction is
computational phantoms.
In the last 50 years, computational phantoms have experienced dramatic advancements,
beginning with the ICRU spherical models (ICRU 1992a) and simple first-generation stylized
phantoms at discrete ages (ORNL 1966) to the advanced age-scalable computational
phantoms (Howell et al 2019) and to the highly realistic patient-dependent hybrid
computational phantom libraries (Lee et al 2010, Segars et al 2010, Zaidi and Tsui 2009, Xu
2014). Taking advantage of the modeling flexibility, the reference size hybrid phantoms were
modified into body size-dependent phantoms such as the phantom library developed by the
University of Florida and National Cancer Institute (UF/NCI) consisting of 158 pediatric
phantoms of various heights and weights (Geyer et al 2014). When using such phantom
library to retrospectively reconstruct RT treatment of a childhood cancer survivor with no CT
images, a phantom of nearest height and/or weight of the survivor can be selected as a
surrogate. This approach is only feasible when both the height and weight of a survivor are
known (Kalapurakal et al 2018), which, however, is not always the case in historic RT records.
Therefore, the age at RT is commonly used as a surrogate for height and weight where
reference size phantoms are adopted. Since the reference size phantoms are usually available
at discrete ages (e.g. newborn, 1, 5, 10, 15, and adult), the nearest available discrete age
would be selected for RT reconstruction for a survivor. For example, the 5-year-old reference
size phantom would be selected for a survivor that was 3.9-year-old at the time of RT
treatment. This age discrepancy, further increases uncertainty in dose reconstruction as the
organ size of a 3.9-year-old survivor would be smaller than that of a standard 5-year-old
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phantom which, (1) for partially in-beam organs, would result in a larger fraction of the
organs being in-beam, overestimating dose and (2) for out-of-beam organs, would result in
organs being farther from the field, underestimating organ dose. Dosimetric uncertainties
can translate to uncertainties in risk estimation, which in some instances can be as much as
70% (Vũ Bezin et al 2017).
Since age is generally the only height and weight surrogate available in historic RT
records, age-based scaling of computational phantoms is frequently used in RT epidemiology
studies. The MD Anderson Late Effects Group developed and validated a computational
phantom (used in over 120 radiation epidemiology studies) that can be scaled to any ages
from infant to adult (Stovall et al 2006, Howell et al 2019) based on age-scaling functions
(ASF) that were developed from growth data of 4,127 U.S. infants, children, and youths
through 18 years of age (Snyder et al 1977). This capability is compatible with what is
typically available in historic RT records and also allows for the scaling of the computational
phantom to the exact age of the survivor at the time of RT treatment. Recently, the MD
Anderson phantom and the ASFs were implemented and validated in the Digital Imaging and
Communication in Medicine (DICOM) standard (Gupta et al 2020). This adaptation makes it
possible to use ASFs to scale other DICOM-formatted phantoms. The main purposes of this
investigation were to (1) conduct a feasibility study to scale reference size discrete age
phantoms from the UF/NCI phantom library to both discrete and continuous valued ages that
are common in RT epidemiologic studies of childhood cancer survivors and (2) to evaluate the
dosimetric impact of using exact age-scaled phantoms as opposed to nearest-age matched
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phantoms. Hereafter, we have interchangeably used discrete aged phantoms to represent
reference size UF/NCI phantoms.

2. Methods
2.1 The University of Florida/National Cancer Institute (UF/NCI) computational phantom
library
We adopted the UF/NCI computational phantoms to test our age-scaling methods. The
phantom library consists of two groups: the reference size phantoms and the body sizedependent phantoms. The reference size phantom library was developed from the manual
segmentations of high-resolution CT scans of cadavers and patients at different discrete ages
from 6 days to 25 years (Lee et al 2010). The phantoms were originally scaled to match the
50th percentile heights, arm lengths, acromial breadth, and body region circumference from
several reference datasets as reported in Lee et al (2010) and Johnson et al (2009). The organ
volumes were represented by a single volume which precluded its comparison with the
International Commission on Radiological Protection Publication (ICRP) 89 data as autopsy
data are mostly reported in terms of wall and internal contents of the organs. Therefore, the
single organ volumes were later separated into organ wall, tissue, blood, and air for discrete
aged phantoms. Furthermore, skeleton, muscles, lymph nodes, and blood vessels were added
to make the phantom more anatomically realistic. With the incorporation of updated organs
and additional structures at discrete ages, the ICRP adopted the UF/NCI pediatric male and
female phantoms (age: 6 days, 1, 5, 10, and 15 years) in ICRP 143 report (Bolch et al 2020).
Later, the heights of the phantoms were up-/down-scaled and the circumference of the body
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regions was modified (by adding fat layer) to create a library of 158 pediatric and 193 adult
phantoms of varying heights and weights i.e. body-mass index (BMI) (Geyer et al 2014). These
phantoms were later converted to DICOM-RT format, with accompanying CT images and
segmented organ structures, using the DICOM-RT Generator developed in Griffin et al (2019).
For our feasibility study, we used reference size male and female UF/NCI phantoms at
ages 1, 5, 10, 15, and 35 years as this phantom set allows us to validate our age scaling
methodologies at discrete ages and also allows us to scale the phantoms to any continuousvalued ages that are common in RT epidemiological studies of pediatric survivors. We
excluded the newborn phantoms because the neck is flexed in these phantoms, which results
in an inherent error due to the difference in neck orientation; we are only interested in
scaling errors from our ASFs.
For our dosimetric assessment, we obtained one reference size 5-year-old UF/NCI
phantom and seventeen body-size dependent phantoms that were created from the
reference 5-year-old phantoms. We selected the age of 5 years in our study because this is
the closest age to the median age of Childhood Cancer Survivor Study (CCSS) cohort
(Leisenring et al 2009, Robison et al 2009) which is adopted in this study to obtain
continuous valued-ages that are common in RT epidemiologic studies (as described in detail
in section 2.4). The age, number, height, and weight of the phantoms used in this study are
shown in Table 4.
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Table 4: Parameters of UF/NCI phantoms selected in this study
Age (years)

Number of
phantoms
M

Heights (cm)*

Weight (kg)

M
F
M
F
Phantoms used in the feasibility study
1
1
1
76.4
76.4
10
10
5
1
1
110.3
110.3
19
19
10
1
1
139.9
139.9
32
32
15
1
1
169.9
161.9
56
53
Adult (35)
1
1
174.8
163.6
73
60
Phantoms used in dosimetric assessment studies
95.35
9
8
95.3-115.5 15-30 15-30
115.5
*Heights were measured from DICOM file. M= male and F=female

Type

F

Reference
Reference
Reference
Reference
Reference
Body-size
dependent

2.2 Modification of MD Anderson Late Effects Group scaling methodologies for UF/NCI
phantoms
2.2.1 Original MD Anderson Late Effects Group scaling methodologies
Our baseline 3D phantom (hereafter called the generic phantom) consists of body
regions that define the head, neck, trunk, legs, and arms, and 25 organs (Stovall et al 2006,
Howell et al 2019). Phantom scaling methods are described in detail in Gupta et al (2020) and
will be summarized here. The generic phantom is scaled by body region and direction-specific
ASFs, which account for non-uniform growth of the generic phantom to any arbitrary age in
right-left (RL) or x, anterior-posterior (AP) or y, and inferior-superior (IS) or z directions. Since
the ASFs are body region-specific, the organs located within each body region are scaled with
the same ASFs as the body region. The ASFs have two components and hence, scaling is
executed in two - steps. In the first step, the body region and direction-specific scaling factors
are determined based on the target age. For the ages a ϵ { 0.1, 1, 3, 5, 10, 15, 18 years}, we
use discrete scaling functions, Fdis , which was originally estimated from 50th percentile body
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measurements reported by Snyder et al (1977). For any other ages, we perform linear
interpolation in between closest discrete ages to estimate the continuous valued age scaling
function, Fcont . In the second step, Fdis or Fcont are incorporated in the body region and
direction-specific transformation equations which transform the 3D points with respect to
the reference lines and boundaries of body regions. For example, in the RL directions, points
were transformed about x=0, and in the AP direction, points were transformed with respect
to the anterior boundary of the body regions. This enables accurate scaling and localization of
the 3D points of each body region and organ. Lastly, since the body regions and organs are in
point format, the points for each structure are converted to surface contours using convex
hull algorithms.
2.2.2 Modifications in scaling factor estimation
Since the UF/NCI phantoms are available at discrete ages, we developed a protocol to
apply our ASFs to scale the UF/NCI phantoms from discrete ages to our generic phantom
dimensions and then scale from the generic phantom dimensions to any arbitrary age.
Therefore, the scaling function, Fa→at , in a head-first-supine orientation, is obtained by taking
the ratio of scaling functions Fdis or Fcont of a specified body region, r, in a direction, d, at an
arbitrary target age, at , and Fdis of the same r in the same direction but at the original
discrete age, a, as shown in equation (9).

Fa→at (d, r, a) =

Fx
Fdis or cont (d, r, at )
F
= [ y]
Fdis (d, r, a)
Fz

9

where:
d ϵ {left to right (x), anterior to posterior (y), and inferior to superior (z)}
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r ϵ {head (h), neck (n), trunk (tr), arms (ar), legs (lg)}
a ϵ {0.1 (1 month), 1, 3, 5, 10, 15, 18}, and
at lies in the age intervals {[0, 1), [1, 3), [3, 5), [5, 10), [10, 15) and [15, 18)}
Fx , Fy and Fz are the scaling factors and are represented in the matrix form.

2.2.3 Modification in transformation equations
Two factors drive the modification of our original transformation equation: the
availability of the UF/NCI phantom in DICOM format and adoption of the RayStation
treatment planning system (TPS), which is currently used in our clinic. The body regions and
organs of the UF/NCI phantom are in 3D region of interest (ROI) format in RayStation and the
TPS has the “TransformROI3D” function where scaling, rotation, and translation factors are
entered in the 4x4 transformation matrix 𝐓 as shown in equation (10). Since the
transformation that is performed in RayStation only involves scaling and translation, all the
rotational components are equal to zero.
Fx
0
𝐓= [
0
0

0
Fy
0
0

0
0
Fz
0

tx
ty
]
tz
1

10

Where, Fx , Fy , and Fz are the scaling factors (from equation (1)) that scale an ROI in the
RL, AP, and IS directions, respectively. t x , t y and t z translate an ROI in the RL, AP, and IS
directions, respectively.
To adapt our original transformation equations (Gupta et al 2020) correctly in the
“TransformROI3D” function, we modified our original approach which we will summarize
here. We first performed scaling of ROIs using scaling matrix 𝐓𝐬 (equation (11)) where
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rotational and translational elements are zero. We then translated the scaled ROI using 𝐓𝐭
(equation (12)) where scaling and rotational elements are zero. Equations (11) and (12) are
the derivatives of equation (10).
Fx
0
𝐓𝐬 = [
0
0

0
Fy
0
0

1
0
𝐓𝐭 = [
0
0

0
1
0
0

0
0
Fz
0

0
0
]
0
1

0 tx
0 ty
]
1 tz
0 1

11

12

If R(x,y,z) is the unscaled 3D ROI that spans the patient in the RL, AP, and IS directions, then
the scaled ROI R T (x, y, z) at an arbitrary age at is obtained by
R T (x, y, z) = 𝐓𝐬 ⋅ R(x, y, z)

13

The above operation results in displacements in the centroids of the body regions and organs
as each body region and its corresponding organs undergo non-uniform scaling. To remedy
this, we first correct the centroids of the body region and then the centroids of the organs
(also presented in Figure 8). For body regions, we first determine the centroid of the scaled
head ROI. Then, we translate it back to centroid before scaling. We then translate all other
scaled body regions to the mid-plane (in AP and RL directions) of the scaled head ROI using
𝐓𝐭 . The translations in IS direction, for correct body region stacking, is determined by scaling
the distance between the centroids of unscaled head and body regions ROI as described in
more detail in Gupta et al (2020). Organs ROI are translated with respect to centroids and
the anterior and upper boundary of the body region they belong to. This results in the
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accurate scaling of the original depth of organs in all directions. Therefore, the centroids
(Xct (o), Yct (o), Zct (o)) of the scaled organ ROI, o, are given by:
Xct (o) = Xct (r) ± abs[Xc (o) − Xc (r)] ⋅ Fa→ at (x, r, a)
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Yct (o) = Yabrt (r) + abs[Yc (o) − Yabr (r)] ⋅ Fa→ at (y, r, a)
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Zct (o) = Zubrt (r) − abs[Zc (o) − Zubr (r)] ⋅ Fa→ at (z, r, a)
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Where,
Xct (r) and Xc (r) are the centroids of the scaled and unscaled body region, r, in the RL
direction, respectively. The + and – signs accounts for the organs located in the right
and left directions, respectively, from the mid-plane of the patient
Xc (o), Yc (o) and Zc (o) are the centroids of unscaled organ, o, in the RL, AP, and IS
directions
Zubrt (r) and Zubr (r) are the upper boundaries of scaled and unscaled body regions, r,
in the IS direction.
Once (Xct (o), Yct (o), Zct (o)) is calculated, the organ ROIs are translated to their correct
centroid using 𝐓𝐭 .
Although UF/NCI phantoms were used in this study, the above methodologies can be applied
to any DICOM-compatible phantom or whole-body patient anatomy for which ROI of the
body regions and organs of interest are available.
2.3 Scaling of computational phantoms to arbitrary ages
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To perform the scaling and generating of DICOM files of the scaled phantoms, DICOM
files of the original phantoms are imported into the RayStation v10B TPS. We developed
Python scripts that can scale any whole-body CT-based anatomy from one age to another as
long as we have organ contours/ROI or points representing the ROI. This task is accomplished
with three different in-house Python scripts using the following steps. A general overview of
the steps for downscaling a 5-year-old to a 3.9-year-old is presented in Figure Error!
Reference source not found.8.
1. Data preparation: The current and target ages of the phantom or patient anatomy
are entered in the Python script. A quality check is performed to ensure that the
phantom is in head-first-supine orientation and the names of all organs within the
phantom match a name from the list of names that are defined in the script.
2. Body region separation: Since the UF/NCI phantom does not have the body regions
defined, we divided the whole-body ROI into head, neck, trunk, arms, and legs based
on standard bony landmark measurements performed on the phantom. For example,
the boundary of the head and neck is at the intersection of the 2nd and 3rd cervical
vertebrae. The separation was performed using ROI algebra in the RayStation TPS.
3. Localization of organ centroids: Distances between the organ centroids and the
boundary of body regions are calculated. In the RL, AP and IS directions, the distance
is calculated with respect to the midline of the patient, the frontal boundary of the
cuboid enclosing the body regions, and the upper boundary of the cuboid enclosing
the body regions. The calculated distances are scaled using equation (9).
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4. Scaling and translation of body regions and organs: Using equations (9) and (13),
each body region is scaled and translated per the description in section 2.2.3. The
organs are also scaled using equations (9) and (13) and are translated using equations
(14)-(16)
5. Post-processing: The boundaries of body regions in the IS direction are checked for
gaps or any unanticipated translation. The manual translation is performed for such
cases. Steps 2 through 4 involve multiple ROI algebra operations, which could result in
small holes in the contours, contour overlaps, and fragments. This is fixed by using the
“Simplify contours” function in RayStation.
6. Assignment of Hounsfield unit (HU) values: Once the phantoms are scaled in the TPS,
the size of the body regions/organs changes in each slice, and as a result, the
contour/ROI boundaries do not cover the same voxels of the CT scan. Because of this,
the HU values originally assigned to each voxel no longer represent the scaled
anatomy. To assign the correct HU values to each voxel, the DICOM files are exported
and are processed with our Python script. The following lists the sub-steps within step
6.
a. Using the polygon function of the skimage.draw Python module (Van Der Walt et
al 2014), we trace the boundary of contours on the slices of CT scan. Using the
traced boundary, we create masks on each slice and then we record the voxel
locations.
b. For discrete ages, we obtain HU values from the DICOM RT generator software
(Griffin et al 2019). For continuous-valued age, we perform linear interpolation to
estimate the HU values.
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c. For each scaled organ ROI, we assign same HU values to each voxel that reside
within the ROI boundary.
The result of step 6 is a CT scan with voxels that are assigned HU values based on the
ROI boundary that a voxel resides in.
7. Quality Check: DICOM files are imported into RayStation TPS and are visually
inspected by the user for artifacts and discontinuity of the voxel HU values at ROI
boundaries. Contours are simplified and holes are removed. Afterward, the DICOM
files are ready for the dose calculations.
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Figure 8: Steps used in the scaling process of the UF/NCI phantoms to arbitrary ages. Scaling
of a reference size 5-year-old to 3.9-year-old is shown as an example.
2.4 Feasibility and validation study
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For the feasibility study using our ASFs, we downscaled both male and female discreteaged phantoms (5, 10, 15 and 35 years) to the nearest lower discrete ages (1, 5, 10 and 15
years), resulting in 8 scaled phantoms (4 male and 4 female), and validated the scaled
phantoms with the original UF/NCI phantoms available at that age, i.e., ground-truth
phantoms. For example, the 5-year-old male phantom was scaled to the size of a 1-year-old
phantom and was validated with a ground-truth 1-year-old male phantom. To show the
feasibility of scaling discrete-aged phantoms to continuous valued-aged phantoms, we
downscaled the nearest age-matched discrete-aged phantoms to three different ages,
representative of the CCSS expanded cohort. Specifically, both male and female 5-year-old
phantoms were downscaled from reference size UF/NCI phantom library to 3.9-year-old
phantoms (median age at RT for Wilms’ tumor patients in CCSS expanded cohort). Similarly,
both male and female 10-year-old phantoms were downscaled to 8.1 and 9.0-year-old
phantoms (median ages at RT for craniospinal tumor patients and for entire CCSS expanded
cohort, respectively). A total of 14 phantoms were downscaled using two methods; 8
phantoms scaled to nearest lower discrete age and 6 phantoms scaled to median ages based
on CCSS participants’ ages at RT.
We used two approaches to validate the scaling of phantoms. In the first approach, we
compared the overlap and organ displacement parameters between the scaled and groundtruth UF/NCI phantoms at discrete ages. In the second approach, we compared the
anthropometric parameters of scaled phantoms with ground-truth phantoms, and with
reference data from ICRP 89 (ICRP 2002) and the Center for Disease Control and Prevention
(CDC) (Centers for Disease Control and Prevention 2000).

50

2.4.1 Quantitative assessment of body region/organ overlap and displacements at discrete
ages
The main goal of quantifying the overlap and the displacement was to determine the
body-regions/organs that are most and least affected by scaling, in terms of their size and
position. To quantify the overlap between two ROIs of a body region/organ, we first
performed rigid registration between the scaled and ground-truth phantoms at discrete ages
using the centroid of the trunk body region. Using built-in functions within RayStation v10B,
we calculated the Dice similarity coefficients (DSC) and mean distance to agreement (MDA)
for the whole-body, brain, heart, liver, pancreas, and kidneys between the scaled and
ground-truth phantoms. The DSC is a measure which calculates the overlap between two
ROIs. The values of DSC ranges from 0 to 1 with 0 indicating no overlap and 1 indicating
complete overlap (Dice 1945). A DSC value of 0.7-0.8 is considered good agreement (Dice
1945, Mattiucci et al 2013, Thomson et al 2014). The MDA estimates the average similarity
between the two ROIs by estimating the average of distance between the point per voxel on
the surface of two ROIs (Brock et al 2017). A value of MDA=0cm represents that the
boundaries of two ROI is perfectly overlapped.
To estimate the displacements in the body regions/organs, we calculated the Euclidean
distance (ED) between the centroids of the body regions/organs of scaled and ground-truth
reference size UF/NCI phantoms using the equation below2

2

𝐸𝐷 = √(𝑥𝑐𝑡 − 𝑥𝑐 ) + (𝑦𝑐𝑡 − 𝑦𝑐 ) + (𝑧𝑐𝑡 − 𝑧𝑐 )

2

17
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where, (xc , yc , zc ) and (xct , yct , zct ) are the centroids of body regions/organs ROIs in
ground-truth and transformed (scaled) phantom, respectively.
2.4.2 Quantitative assessment of anthropometric parameters at all ages
The goal of assessing the anthropometric parameters was to gauge the standing
heights and organ masses of the scaled phantom with respect to reference data. First, we
compared the standing heights of the scaled phantoms with those of the ground-truth
phantoms at discrete ages and reference data from CDC at all ages. Specifically, we calculated
the percent difference (equation (18)) between the standing heights of scaled phantoms, and
(1) heights of the ground-truth phantoms, and (2) CDC-reported 50th percentile heights for all
14 scaled phantoms.

𝑃𝐷 =

𝑆ℎ − 𝐺ℎ
× 100
𝐺ℎ

18

Where, Sh is the height of a scaled phantom and Gh is the height from a ground-truth
phantom or CDC data.
Second, we compared the scaled organ masses with ICRP 89 reference data. First, we
estimated the mass of the scaled organs by taking the product of the organ volumes from
RayStation and ICRU 46 reported reference densities (ICRU 1992b). We then calculated the
difference between the masses of scaled organs and ICRP 89 reported organ masses. The
calculation was performed for brain, heart, lungs, liver, stomach, and kidneys and all of the
male and female discrete-aged phantoms, as ICRP 89 data are unavailable for 3.9-, 8.0-, and
9.1-year-old phantoms. For lungs and kidneys, combined masses of left and right organs were
compared.
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2.5 Difference in organ dose due to scaling- Wilms’ Tumor RT plan example
In historic RT cohorts, dose reconstructions are based on treatment parameters
abstracted from the RT records, including field size and field location (based on anatomical
landmarks). In such studies, patients’ heights and weights or CT images are not always
available. Thus, if one were to do the dose reconstructions for survivors at continuous-valued
ages, the nearest age-matched phantom would be selected, and the coded field would be
reconstructed on that phantom. In this scenario, a patient’s coded field size would not be
adjusted in size for the differences in age between the patient and the closest age-matched
phantom. However, in contemporary treatments, RT records include patients’ height and
weight and CT images at the time of RT. In this scenario, with the anatomical information, the
field sizes could be appropriately adjusted to better align with the anatomical landmarks
from the RT records. Therefore, in our dosimetric assessment, we considered both scenarios
and performed a dosimetric assessment between the exact age-scaled and nearest agematched discrete-aged phantoms by designing typical RT plans in RayStation TPS for Wilms’
tumor as this is one of the common pediatric cancers in the CCSS.
In the first study, we downscaled a reference size 5-year-old phantom to a 3.9-year-old
and constructed right flank fields identical in size on both the 3.9-year-old and 5-year-old
phantoms. Specifically, 6 MV AP/PA right flank fields were simulated on a 3.9-year-old with
the superior field border at 2 cm below the liver/heart boundary, the inferior border at the
5th lumbar vertebrae, the right border at a 1 cm margin enclosing the liver, and the left
border enclosing the vertebral bodies. A total of 20Gy was administered to the isocenter
placed at midplane in AP/PA direction. We then measured the size of the simulated field and
53

reconstructed an identical pair of AP/PA flank fields on a 5-year-old phantom. The volume
receiving ≥ 15Gy (V15), and the mean dose to pancreas, liver, and stomach were calculated.
Absolute difference and percent difference were calculated for both phantoms’ RT plans.
In the second study, we scaled a cohort of seventeen body size-dependent UF/NCI
phantoms (9 male and 8 female) of created from the 5-year-old reference phantom to 3.9year-old and simulated the same standard Wilms’ tumor 3D conformal RT plan on all 34
phantoms. All of the treatment parameters were the same as the 3.9-year-old of the first
study except the field size, which varied to maintain identical field borders. Specifically, the
superior and inferior field borders were set at 2 cm below the liver/heart boundary and the
level of the 5th lumbar vertebrae, respectively. The medial field border was set enclosing the
thoracic vertebrae. Dose to organs that were either fully or partially in-beam was calculated.
Here, we compared the percent of volume receiving ≥ 15 Gy (V15), mean dose, and minimum
dose received by 1% (D1) and 95% (D95) between the 5-year-old phantoms and the
corresponding 3.9-year-old phantoms. Organs included the pancreas, liver, stomach, left
kidney (contralateral), right kidney, right and left colons, gallbladder, thoracic vertebrae, and
lumbar vertebrae. To determine if the dose and dose-volume metrics were significantly
different between treatment plans for the different phantoms, we performed a nonparametric Wilcoxon rank sum test using the SciPy package of the Python programming
language. Medians, standard deviations, and p-values (p<0.05 is significant) are reported for
each metric.
3. Results
3.1 Feasibility of scaling UF/NCI phantoms to continuous-valued ages
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The feasibility of downscaling the reference size UF/NCI phantoms to any arbitrary age
using our ASF and transformation function is demonstrated in Figure 9. The figure shows the
downscaled phantoms in standing positions next to their nearest age-matched discrete-aged
phantom. An important finding of the scaling is that the structural integrity of the phantoms
is maintained after the scaling, i.e., all of the organs and body regions remained intact with
no unexpected organ displacement or gaps between body regions

Figure 9: Downscaling of UF/NCI nearest age-matched discrete-aged pediatric male
phantoms (5-year-old and 10-year-old phantoms) to median ages (3.9 years for Wilms’
tumor, 8 years for all cranial tumors, and 9.1 years for all individuals from the CCSS expanded
cohort) of different CCSS cohorts.
3.2 Quantitative assessment of overlaps and displacements due to scaling at discrete ages
55

The DSC, MDA, and ED between the scaled and ground-truth reference size phantoms at
discrete ages for the whole-body ROI and organ ROIs are presented in Figure 10. The wholebody and brain showed good ROI overlap with median (range) DSCs of 0.91 (0.86-0.92) and
0.86 (0.58-0.91), respectively. The heart and liver showed average agreement after scaling
with median DSC of 0.70 (0.61-0.78) and 0.74 (0.38-0.80), respectively. The kidneys and
pancreas had the poorest overlap agreement with low DSC values of 0.58 (0.45-0.74) and
0.32 (0.01-0.62), respectively.
Additionally, the liver, pancreas, and heart showed larger MDA values (i.e. ROI shape
variations) compared to the other organs. Specifically, the median (range) MDA for liver,
pancreas, and heart were 0.73cm (0.43-1.79cm), 0.78cm (0.47-2.29cm), and 0.68cm (0.471.1cm), respectively, while the median MDAs for the whole body, brain, and kidneys were
0.65cm (0.47-0.93cm), 0.51cm (0.34-1.7cm) and 0.62cm (0.29-0.98cm), respectively.
However, those difference are not very meaningful as the box plot overlaps mostly.
The brain showed the smallest range of ED displacements with a median ED of 0.97cm
(0.58-3.67), while the pancreas, whole-body, heart, kidneys and liver showed median EDs to
2.03cm (0.72-3.82), 1.35cm (1.04-2.3cm), 1.33cm (0.39-1.9cm), 1.04cm (0.41-2.79cm), and
0.97cm (0.58-4.09cm), in case of whole-body, heart, liver, pancreas and kidneys,
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respectively. The liver showed the highest ED displacement (4.09cm) among all organs.

Figure 10: [a] Dice similarity coefficients (DSC), [b] mean distance to agreement (MDA), [c]
Euclidean distance (ED) between the scaled and ground-truth phantoms at discrete ages for
whole-body and five different organs are shown. Means are represented by white square
boxes.
3.3 Comparison of anthropometric parameters
The overall trends in standing heights and the percent difference/absolute difference
between the standing heights of the scaled phantom and reference data (UF/NCI and CDC)
are shown in Figure 11 and Table 5 at all studied ages. In Table 5, the data are segregated
into discrete and continuous-valued ages. Overall, the heights of the scaled phantoms were
within 6.3% (6.9cm) of the ground-truth phantom and CDC 50th percentile height data. Better
agreement (within 3% or 3.9cm) was observed in the case of the discrete-aged phantom as
compared to the phantoms of continuous-valued age.
The scaled masses (in grams) of seven different organs and the absolute difference
compared with ICRP 89 reported masses are listed in Table 6 for all the discrete-age scaling.
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For all cases, the masses of the brain, pancreas, and kidneys of the scaled phantom were
smaller than their ICRP 89 counterparts, as indicated by negative differences. However, the
masses of the scaled lungs and stomach were larger than those in the ICRP 89 data. Lastly,
except for the 1-year-old phantom, the masses of the scaled heart and liver were smaller
than those of the ICRP 89 phantoms. Overall, we obtained an absolute difference ranging
from 0.4g to 340g across all of the studied organs and ages.

Figure 11: Trend of standing heights of scaled phantoms with respect to original UF/NCI
phantoms and CDC reported 50th percentile heights for both male and female.
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Table 5. Comparison of standing heights of scaled phantom heights with ground-truth UF/NCI
phantom heights and with CDC reported 50th percentile heights
Scaled Heights (cm)

Age**

Male

Female

Percent Difference (%)
UF/NCI

UF/NCI

Male*

Female*

CDC
Male*

CDC
Female*

Discrete ages
1 (5)

76.2

76.2

0.4 (0.3)

0.4 (0.3)

0.1 (0.1)

2.4 (1.8)

5 (10)

110.6

110.6

0.3 (0.3)

0.3 (0.3)

1.3 (1.4)

3.0 (3.2)

10 (15)

139.9

136.0

0.0 (0.0)

2.8 (3.9)

0.8 (1.1)

1.3 (1.8)

15 (Adult)

169.5

158.9

0.3 (0.5)

1.9 (3.0)

0.1 (0.2)

1.8 (2.8)

Continuous-valued ages †
3.9 (5)

102.6

102.6

6.3 (6.9)

5.5 (5.9)

1.1 (1.2)

2.7 (2.7)

8 (10)

128.3

128.3

4.5 (6.0)

2.8 (3.7)

0.1 (0.2)

0.4 (0.5)

9.1 (10)

134.8

134.8

3.2 (4.5)

1.4 (1.9)

0.5 (0.6)

1.0 (1.3)

*Absolute difference is shown in the parenthesis (in cm). **Original age of the phantom that
was used for downscaling is shown in parenthesis i. †Power law fit was used to estimate the
ground-truth heights of UF/NCI phantoms for non-discrete ages.
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Table 6: Comparison of scaled organ masses of UF/NCI computational phantoms with ICRP 89 reference masses.Scaled masses and
difference between the scaled and ICRP 89 reference masses are reported. All masses are in grams.
1-year-old

5-year-old

10-year-old

15-year-old

SM

SF

SM-ICM

SF-ICF

SM

SF

SM-ICM

SF-ICF

SM

SF

SM-ICM

SF-ICF

SM

SF

SM-ICM

SF-ICF

Brain

896.1

896.3

-53.9

-53.7

1158.0

1158.1

-152.0

-21.9

1311.5

1199.5

-88.5

-20.5

1326.7

1196.7

-93.3

-103.3

Heart

125.3

125.3

27.3

27.3

198.4

198.5

-21.6

-21.5

356.0

291.8

-14.0

-78.2

636.4

469.4

-23.6

-70.6

Lungs

106.9

106.9

26.9

26.9

174.3

174.2

49.3

49.2

373.7

357.2

163.7

147.2

669.1

547.9

339.1

257.9

Liver

330.6

330.7

0.6

0.7

451.0

451.2

-119.0

-118.8

714.0

717.1

-116.0

-112.9

1391.5

1082.5

91.5

-217.5

Stomach

77.0

76.9

57.0

56.9

110.0

110.0

60.0

60.0

170.1

175.2

50.1

55.2

306.4

285.7

156.4

145.7

Pancreas

19.6

19.6

-0.4

-0.4

31.4

31.4

-3.6

-3.6

57.5

54.4

-2.5

-5.6

105.2

91.1

-4.8

-8.9

Kidneys

65.7

65.7

-4.3

-4.3

101.3

101.2

-8.7

-8.8

140.9

135.8

-39.1

-44.2

242.1

216.5

-7.9

-23.5

SM=Scaled masses of UF/NCI male phantoms; SF = scaled masses of UF/NCI female phantoms; ICM = ICRP 89 reference masses of male; ICF = ICRP 89 reference masses of female
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3.4 Comparison of Wilms’ tumor RT plan dose of exact age-scaled and nearest age-matched
phantoms
The results of the dosimetric study, in which the same field size and same isocenter were
used for the Wilms’ tumor treatment plans for a 3.9-year-old downscaled from a reference
size 5-year-old and an original unscaled reference size 5-year-old phantom, are reported in
Table 7 and Figure 12. The beam’s eye view and isodose washes for the 3.9-year-old are
shown in 12a and 12c, and those for a 5-year-old are shown in 12b and 12d, respectively. In
the isodose washes, dose coverage of the organs differed between the 3.9-year-old and the
5.0-year-old. For example, different fractions of the pancreas and liver are enclosed within
the 75% isodose line (15 Gy). As a result, the absolute differences in V15 of pancreas and liver
were 3.52% and 5.98%, respectively (Table 7). Results for all organs and dose metrics are
listed in table 7.
Results from the dosimetric study where the field borders relative to anatomical
landmark were consistent for all phantoms (resulting in different field sizes) are listed in
Table 8 and illustrated in Figure 13. V15 and mean dose were significantly different between
exact age-scaled and nearest age-matched phantom in all other organs except for the right
kidney (target), right colon, and gallbladder. The contralateral kidney was significantly
different between phantoms in all dose metrics except D95. Similarly, liver and pancreas were
significantly different in all except D1 and D95, respectively. Figure 13 shows the distribution
of metrics for selected near beam organs; pancreas, liver, contralateral kidney, and stomach.
In all organs and metrics, the median and mean were higher in the case of the original 5-yearold phantom.
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Figure 12: Digitally reconstructed radiograph of a Wilms’ tumor plan for (a) a 3.9-year-old
downscaled from a reference size 5-year-old and (b) an unscaled reference size 5-year-old.
Isodose wash for liver, stomach, kidneys, and pancreas of (c) the downscaled and (d) the
unscaled phantoms for 5% (cyan), 75% (blue), 95% (purple), 100% (yellow), and 110% (red) of
the prescription dose. Except vertebral bodies, no bones were downscaled.
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Table 7: Absolute and percent difference between the V15 and mean dose
from 6MV Wilms’ tumor RT plan (20 Gy to right kidney) between
unscaled reference size 5-year-old and 5-year-old downscaled to 3.9-yearold
V15, in %
Mean Dose, Gy
Organs
Abs. diff % diff
Abs. diff % diff
Pancreas
3.52
42.04
0.85
4.25
Liver
5.98
8.61
1.29
6.45
Stomach
0.00
0.00
0.11
0.55
% difference in mean dose is normalized to 20 Gy
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Table 8: Metrics investigated to establish the difference in dose from 6 MV Wilms’ tumor RT plan (20 Gy to right kidney) in between
3.9-year-old and 5.0-year-old phantoms. Wilcoxon rank sum test was performed to determine if differences were statistically
significant (p<0.05 is significantly different)
V15 (in %)
Mean Dose (Gy)
D1 (Gy)
D95 (Gy)
3.9y
5.0y
3.9y
5.0y
3.9y
5.0y
3.9y
5.0y
P-Val
P-Val
P-Val
P-Val
Med.
Med.
Med.
Med.
Med.
Med.
Med.
Med.
Pancreas
16.86
19.55
<0.05
4.40
4.75
<0.05
19.13
19.15
>0.05
0.32
0.33
>0.05
Liver
66.68
70.71
<0.05
14.38
14.86
<0.05
20.97
21.02
>0.05
1.20
1.32
<0.05
Lt. Kidney
0.01
0.40
<0.05
1.55
1.78
<0.05
9.31
10.78
<0.05
0.72
0.73
>0.05
Rt. Kidney
100.00
100.00
>0.05
20.07
20.11
>0.05
20.62
20.68
>0.05
19.60
19.62
>0.05
Rt. Colon
68.08
67.63
>0.05
14.66
14.60
>0.05
21.29
21.35
>0.05
0.59
0.58
>0.05
Lt. Colon
15.30
15.90
<0.05
4.14
4.36
<0.05
19.76
19.84
>0.05
0.30
0.30
>0.05
Stomach
0.44
0.59
<0.05
0.87
0.99
<0.05
7.59
9.56
<0.05
0.29
0.30
>0.05
Gallbladder
100.00
100.00
>0.05
19.78
19.80
>0.05
20.00
20.03
<0.05
19.57
19.58
>0.05
T. Vertebra
14.29
15.50
<0.05
3.08
3.37
<0.05
19.32
19.35
>0.05
0.00
0.00
<0.05
L. Vertebra
97.81
98.47
<0.05
18.96
19.04
<0.05
19.95
20.00
>0.05
17.29
17.50
>0.05
V15 = percent of volume receiving ≥ 15Gy; D1 is dose received by 1% of the volume; D95 is dose received by 95% of the volume. Blue label highlights the significantly different cases; Rt. and Lt. colon
stands for right and left colon respectively. T. and L. vertebra stands for thoracic and lumbar vertebra. Med. indicates median.
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Figure 13: Boxplot showing the V15, mean dose, D1, and D50 for pancreas, liver, left kidney,
and stomach. All of the results presented here are significantly different (p<0.05, N=17)
except D95 for left kidney, D1 for the liver, and D95 for the stomach. Mean is represented by
the white box.
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4. Discussion
In this study, we have successfully scaled the realistic CT-based UF/NCI pediatric
reference phantom to arbitrary ages using our ASFs, which is also a proof-of-concept that our
ASFs can be used to accurately scale any CT-based anatomy. We have also established that
dose to organs in between the cohorts of age-specific (continuous-valued age) and nearest
discrete age-matched phantoms varies significantly (p<0.05). This is an indication that using
an exact age-scaled phantom is an important consideration for dose reconstruction studies.
Our ASFs are functions of age, direction and body region, and are primarily used in
retrospective organ dose reconstruction studies where phantom or patient’s anatomy must
be generated at the time of RT. Currently, there exists a different types of protocols for
selecting phantom as surrogate anatomy: one would select phantom by matching the heights
and weights of the patient or select the nearest age phantom or select the phantom based on
the anthropometric parameter of the trunk from the CT scan at the time of treatment
(Whalen et al 2008, Kuzmin et al 2018). However, for retrospective studies such as in the
CCSS (N>13000 with RT) where patients were treated in the pre-CT era, age is the only most
common, and often the only anthropometric parameter that is available retrospectively. In
such a many case, matching the height and weight of the phantom or matching the
anthropometric parameter of the trunk is not feasible. One would attempt to select a
nearest-age phantom instead of a continuous-valued age phantom; however, such protocols
are associated with higher uncertainties in organ shape and size/volume, that can translate
to uncertainty in organ dose reconstruction and hence in risk assessment (Kry et al 2007,
Whalen et al 2008, Morton et al 2013). Our age scaling methodologies overcome these
limitations as they can accurately scale any phantom of choice or CT-based anatomy to the
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patient’s age at the time of treatment. Furthermore, our ASFs roughly require 3 minutes to
scale a phantom in TPS which also ensures it suitability in the large cohorts. Lastly, our ASFs
have been used to scale our in-house phantoms for other cohorts such as the St. Jude
Lifetime, Adult Life after Childhood Cancer in Scandinavia, and the Dutch Childhood Oncology
Group over three-decade (listed in Howell et al (2019)).
Our feasibility study showed reasonable accuracy in the context of overlap and
displacement metrics for the whole body and various organs. While the whole-body and
brain showed the best DSC scores, the heart and liver scores were still acceptable as they
showed median DSCs of 0.69 and 0.73, respectively which means 50% of the distribution are
>0.7 which is considered a good DSC values (Dice 1945, Zou et al 2004). As reported in
section 3.2, the pancreas and kidneys showed poor DSC agreement as the median DSCs were
at 0.32 and 0.58, respectively, but this cannot be solely attributed to an error in
transformation and scaling as the heart and liver should have also shown poor agreement
because all organs in trunk use same scaling factors. It is important to note that the UF/NCI
phantoms at different ages are not from the same/single patient, which introduces interpatient variation in in organ shape, size, and position (Lee et al 2010). Furthermore, another
reason could be attributed to the sensitivity of DSC to the volume of the organ. For example,
a 1 cm displacement could affect the pancreas/kidneys more than the brain which has a
larger volume. The large ED for the liver and pancreas in our study was not unexpected as
studies of adult patients have reported high range of motion for these organs. One study
reported motion of up to 5.7 cm in the liver (Davies et al 1994, Langen and Jones 2001), while
another study reported motion of up to 8 cm in liver and pancreas (Suramo et al 1984,
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Langen and Jones 2001). This organ displacement also contributed to the poor agreement we
observed in DSC and MDA.
In the anthropometric assessment of scaled phantoms, the scaled standing heights
agreed within 6.3% (6.9 cm) of the reference data. Higher disagreements data were confined
to continuous-valued ages, likely because we used a power law to interpolate the heights of
the UF/NCI phantoms at discrete ages to obtain heights at continuous-valued ages. With
regard to organ masses, we observed ICRP 89 masses were greater than scaled organ masses
except for the stomach and lungs, where ICRP 89 is smaller. Although the scaled masses
highly deviated from the ICRP 89 masses, the scaled masses for organs such as the brain,
lungs, liver, and kidneys for 1-, 5-, and 10-year-old are well within the range of masses
reported in the US population autopsy study by Molina et al (2019).
For the dose study, our investigation using the same field size on exact age-scaled versus
nearest age-matched phantoms showed differences in V15 and mean dose up to 6% and 1.3
Gy (6.45%), respectively. We used the same field size because, in retrospective dose
reconstruction, one would not modify the original field size when using an age-matched
phantom instead of an exact-age phantom. The reason behind the differences is mostly the
shape and position of the organs which varied across exact age-scaled and nearest agematched phantom. In dose reconstruction studies, it has been found that organ shape,
volume, position, dose reconstruction method, irradiation sources, etc. are the major sources
of uncertainty in dose estimation. Furthermore, Kry et al (2007) estimated that a 50%
uncertainty in dose estimation could result in a significant difference in risk of a second
cancer. Therefore, an uncertainty of 6% in V15 or 6.45% in mean dose can potentially affect
the risk estimation studies when they are combined with other sources of uncertainties.
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Additionally, a difference of 1.3 Gy can also affect the risk estimation study if the doses are
finely binned and organ dose values (not the difference) falls at the edge of the bin. Those
impacts will be pronounced when the cohort size is large. Furthermore, it is also important
to determine the effect of scaling on the field size and hence on the organ dose. Our second
study showed that V15 and mean dose were significantly different (p<0.05) except for the
organs that are fully inside the beam. This result was expected because those organs received
roughly 100% of the prescribed dose in each case.
While we have successfully demonstrated the feasibility of scaling the phantoms to any
arbitrary age using our in-house ASFs and have established the difference in dose between
exact-age and nearest age-matched phantoms, our study also revealed that our ASFs need
enhancements. Specifically, in the current study, the underestimation and overestimation of
the organ masses (as shown in Table 6) suggest our ASFs could be enhanced with organspecific ASFs in addition to our current body region-specific ASFs. However, it is worthwhile
to highlight that the scaled masses fell within the range of autopsy masses as discussed
earlier.
Our current ASF-related enhancement includes the development of scaling factors based
on the percentile height of the U.S. population. We are combining our ASFs and CDCreported percentile specific-heights to generate percentile specific ASFs. This will allow us to
scale the phantom based on these heights, which will be available in modern CCSS cohorts.
For modern cohorts in the CCSS, the survivor data will be present in the CT scans, where we
can measure body region-specific parameters such as size, volume, and circumference. We
can use those parameters to estimate the BMI of the patients and develop modulation
factors to generate cohort-specific ASFs. Finally, our group is enhancing/developing individual
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organs (e.g. heart, colon, etc.) within our in-house phantom, which involves the incorporation
of modulation factors into scaling methodologies. For example, Shrestha et al (2020)
introduced a modulation factor based on inherent differences in the trunk size of a UF/NCI
phantom and an MDA phantom to develop a new CT-based hybrid heart before integrating it
into the generic phantom.
5. Conclusion
We have successfully implemented our ASFs to scale UF/NCI phantoms from one age to
another age and have validated the scaling process with reasonable accuracy in terms of
geometric and anthropometric parameters. We have also established that there exists a
significant difference in dose to organ between populations of exact age-scaled continuousvalued phantoms and nearest age-matched discrete aged phantoms. The implementation and
validation allow us to scale - UF/NCI phantoms or any CT-based patient anatomy for RT
epidemiological study using cohorts where age is the main parameter.
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Chapter 5: Discussions and Conclusion
1. General Overview
The primary purpose of this thesis was to implement our FORTRAN phantom and its
ASFs in DICOM format within a commercial TPS so that our dose reconstruction methods can
be used to estimate organ doses of survivors treated with contemporary RT plans. Our
central hypothesis was to implement the phantom within 3% of the FORTRAN phantom with
scaled heights within 7% of the CDC reported 50th percentile heights. To achieve our purpose,
we established two specific aims, all of which were successfully completed by developing
several Python scripts in RayStation TPS.
Our first aim was to accurately model and validate our computational phantom and
its ASFs in DICOM format. We validated our implementation by calculating percent
differences in corner points, volume, and scaled heights of the DICOM phantom and
reference data. All of the metrics were well within limits set in our central hypothesis. Most
of the discrepancies in modeling were attributed to the removal of the negligible gap present
in between the body regions of our generic phantom. The conversion of our organs from
point form to surface contours enabled us to estimate dose to organ ROIs for the first time.
Our dose metrics for partially in-beam organs from TPS agreed within 0.07Gy (mean dose) of
the results from the fully validated in-house dose calculation method. That supported our
hypothesis that our phantom is ready to be used for dose calculation studies within a TPS.
The validation of our ASFs in aim 1 inspired us to scale other whole-body CT-based
phantoms using our age-scaling methodologies. We adopted UF/NCI phantoms to test the
feasibility and successfully scaled the phantoms to arbitrary ages using our ASFs. To assess
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the dosimetric impact of scaling, we designed a study in which we constructed standard
Wilms’ tumor plan of a CCS on an exact age-scaled phantom and the nearest age-matched
phantom. The phantom selection based on a nearest anthropometric parameter such as age
is pretty standard when the exact age phantom is unavailable. Our study showed this could
lead to uncertainty in dose metrics such as up to 6% and 1.3Gy in V15 and mean dose,
respectively, when field size was kept the same between the two phantom types. Since the
risk-assessment studies report doses in bins, a difference of 6% or 1.3Gy alone could not
affect the risk-assessment results. However, the dose-reconstruction methodologies include
uncertainties due to various sources, as reported in Vũ Bezin et al (2017) and Xu et al (2008).
Therefore, a 6% uncertainty in combination with other sources could exceed a total
uncertainty of 50%, which has been estimated to affect risk-assessment studies significantly
(Kry et al 2007, Vũ Bezin et al 2017).
2. Project Limitation and Future Directions
A retrospective analysis of our two aims revealed several aspects of projects that can
be improved. First, in aim one and aim 2, we found that the scaled organ masses were
smaller than the masses from reference phantoms and autopsy. In aim 2, most of the
discrepancies in height were confined to female data. Such discrepancies could be improved
if we have ASFs specific to the population's organ, sex, and percentile height. A preliminary
study has already been conducted to develop percentile-specific ASFs. We modified our ASFs
in AP, IS, and RL by using modulation factors that would match the scaled heights of the
phantom to CDC-reported percentile-specific heights at discrete ages. Figure 14 and 15 shows
the preliminary results of using percentile specific ASFs.
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Figure 14: Evolution of ASFs as a function of age and percentile heights for different ages.
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Figure 15: Change in the volume (volume is shown in white) of heart, liver, and colon (test
model) as a percentile-based ASF function is shown for 5-year-old.
Another project that we would like to work on is the use of ASFs to scale ICRP 143
pediatric reference phantom. ICRP 143 adopted the reference size UF/NCI phantom, which
makes the phantom standard for use in dosimetry studies. Several modifications, such as the
development of organ substructures, the addition of lymph nodes, and overall enhancement,
were performed before ICRP adopted this phantom. A visual comparison between two
phantoms at five years of age is shown in Figure 16, which shows the advancement of
anatomy. Therefore, using ASFs to scale the organs with substructure will be a new addition
to our current feasibility studies.
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Figure 16: Comparison of a 5-year-old ICRP 143 and UF/NCI male and female phantoms
(armless version)
Another major study that our group would like to calculate the accuracy of out-offield dose in the RayStation treatment planning system. Such studies are essential because,
for late effects studies, near beam and far beam organs are of significant interest and TPS are
not accurate for those organs. The quantification of accuracy will allow us to incorporate
modulation factors in our dose-reconstruction method for cohorts treated with
contemporary RT. A previous study from our group was conducted for Pinnacle TPS when
primarily used in our clinic (Howell et al 2010a).
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3. Conclusion
Our results show that we have accurately implemented our computational phantom
and its ASFs in the DICOM format. The phantom and ASFs can be used for dose calculation of
studies. We have also validated that our ASFs can be used to scale whole-body CT-based
anatomy. One major recommendation that this thesis project suggests is using exact agescaled phantom over nearest matched phantom in dose reconstruction studies is an
important consideration.
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Appendices
Appendix A: Mathematical calculations showing transformation of our generic phantom to
7.0-year-old phantom
This appendix is obtained from the following peer-reviewed publication:
A.C. Gupta, S. Shrestha, C.A. Owens, S.A. Smith, Y. Qiao, R.E. Weathers., P.A. Balter, S.F. Kry,
and R.M. Howell, “Development of an age-scalable 3D computational phantom in DICOM
standard for late effects studies of childhood cancer survivors,” Biomedical Physics and
Engineering Express. Volume 6, Issue 6, pages 1-15. © IOP Publishing Ltd.
This work is licensed under a Creative Commons Attribution 4.0 license. It is attributed to
Aashish C. Gupta, Suman Shrestha, Constance A. Owens, Susan A. Smith, Ying Qiao, Rita E.
Weathers., Peter A. Balter, Stephen F. Kry, and Rebecca M. Howell, and the original version
can be found here.

We present a sample calculation following the steps in Figure 3 to illustrate how our
generic “adult” phantom is transformed to a 7.0-year-old phantom. Due to the symmetric
nature of a cube, if two corner points describing a diagonal of the cube are known, then we
can calculate the remaining six corner points of the cube. Hence, we only present the
transformation of two opposite corner points for each of the phantom’s cuboidal body
regions. Additionally, we illustrate the transformation of one point in an organ within the
trunk body region.
Step 1: Import Data
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In this step, we import the organ points and corner points of the body region from the
FORTRAN generic phantom into a DICOM file present in RayStation. To begin, pr and q r
represent the two opposite corners of the cube. Here r ϵ {upper head (uh), lower head (lh),
neck (n), trunk (tr), arms (ar), legs (lg)}. The body regions with their opposite corner points
are presented in the table below.
Table 9: Opposite corner points describing the main diagonal of each
body region in the generic phantom. The corner points are scaled and
translated using equations (1) through (6) to obtain the phantom of
age 𝐚.
Head (upper and
lower)
Neck
Trunk

puh (−2.30, 1.00, 0.00) and q lh (2.30, 6.70, 4.80)

pn (−1.20, 6.70, 1.10) and q n (1.20, 7.60, 3.50)
ptr (−4.00, 7.60, 0.10) and q tr (4.00, 24.00,
4.90)
Leg
plg (−2.80, 24.00, 1.10) and q lg (2.80, 43.20, 3.60)
Arm*
par (4.00, 8.00, 1.60) and q ar (5.60, 21.60, 3.20)
* In table 9, we present the calculation for the right arm only due to
symmetry in approach.
To illustrate how organ points are transformed, we chose the point (-3.40, 14.30, 2.60) in the
liver.
Step 2: Select Phantom Age
Here, we select the age of the phantom as 7.0 years.
Step 3: Transform Coordinates
Based on the user-specified age, we use equations (1) through (6) to transform the points
of the generic phantom to a phantom of age 7.0 years. The process can be divided into two
phases, (i) calculation of the scaling factor and (ii) scaling/translation of generic phantom
points.
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In phase (i), we identify the age group and access the preloaded scaling factor data for the
lower and upper age bounds. Here, the age of 7.0 years falls within the category [5, 10). To
calculate the scaling factor for 7.0 years, we use equation (2), which requires the scaling
factors for upper and lower age bounds (a− ). The scaling factors corresponding to a− = 5.0
and a+ = 10.0 for each body region are presented in Table 10.
Table 10: Scaling factors corresponding to the ages of 5.0 and 10.0
years are shown as age=7.0 𝝐 [5.0,10.0)
Age = 5.0
Age = 10.0
(LR (x), SI (y), AP (z))*
(LR (x), SI (y), AP (z))*
Head
(3.022, 3.286, 3.872)
(3.130, 3.464, 3.957)
Neck
(3.292, 3.026, 3.292)
(3.500, 3.410, 3.500)
Trunk
(2.250, 2.442, 2.653)
(2.750, 3.018, 3.163)
Leg
(3.750, 2.474, 3.840)
(4.583, 3.411, 5.120)
Arm
(3.125, 2.647, 3.125)
(4.000, 3.493, 4.000)
*LR=Left to Right, SI=Superior to Inferior, AP=Anterior to Posterior directions

𝐅𝐜𝐨𝐧𝐭 (𝐱, 𝐮𝐡, 𝟕) = 𝐅𝐝𝐢𝐬 (𝐱, 𝐮𝐡, 𝟓) +

𝟕. 𝟎 − 𝟓. 𝟎
(𝐅 (𝐱, 𝐮𝐡, 𝟏𝟎) − 𝐅𝐝𝐢𝐬 (𝐱, 𝐮𝐡, 𝟓))
𝟏𝟎. 𝟎 − 𝟓. 𝟎 𝐝𝐢𝐬

Fcont (x, uh, 7) = 3.022 +

7.0 − 5.0
(3.130 − 3.022) = 3.065
10.0 − 5.0

The above calculation is repeated in all three directions for each body region, and we finally
obtain all scaling factors for age 7.0 years (Table 11). For the organ points, the same
calculations are repeated based on the body region in which the organ point lies.
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Table 11: Scaling factors for each body region to scale the
phantom from generic to age 7.0 years
(𝐋𝐑 (𝐱), 𝐒𝐈 (𝐲), 𝐀𝐏 (𝐳)) ∗
Head

(3.065, 3.357, 3.906)

Neck

(3.375, 3.180, 3.375)

Trunk

(2.450, 2.672, 2.857)

Leg

(4.083, 2.849, 4.352)

Arm

(3.475, 2.985, 3.475)

*LR=Left to Right, SI=Superior to Inferior, AP=Anterior to Posterior directions
In phase (ii), the body region corner points and the organ points are transformed using
equations (3) and (6). The transformation of each body region is shown in the subsections
below.
Transformation of the head corner points:
For puh (−2.30, 1.00, 0.00):
xt = x ⋅ Fcont (x, r, a) = −2.30 ⋅ 3.065 = −7.05 cm
uh

yt = ∑ luh ⋅ Fcont (y, uh, 7) = (y − ysbr ) ⋅ Fcont (y, uh, 7) = (1.00 − 1.00) ⋅ 3.357
r=uh

= 0.00 cm
zshift =

Zhead ⋅ F(z, uh, 7) − Zhead ⋅ F(z, uh, 7)
= 0.00
2

zt = (z − zabrr ) ⋅ F(z, uh, 7) + zshift = 0.00 ⋅ 3.906 = 0.00 cm
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For q uh (2.30, 6.70, 4.80):
xt = 2.30 ⋅ 3.065 = 7.05 cm
yt = (yibruh − ysbruh ) ⋅ Fcont (y, uh, 7) + (y − yibruh ) ⋅ Fcont (y, n, 7)
= (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 = 18.62 cm
zshift =

Zhead ⋅ F(z, uh, 7) − Zhead ⋅ F(z, uh, 7)
= 0.00
2
zt = 4.80 ⋅ 3.906 = 18.75 cm

Transformation of the neck corner points:
For pn (−1.20, 6.70, 1.10):
xt = −1.20 ⋅ 3.375 = −4.05 cm

Since the superior boundary of the neck on the y-axis is the same as the inferior boundary of
the lower head, the transformed point is the same as that obtained for the lower boundary of
the head on the y-axis.

zshift =
=

Zhead ⋅ F(z, uh, a) − Zn ⋅ F(z, n, a)
2

(4.70 − 0.00) ⋅ 3.906 − (3.50 − 1.10) ⋅ 3.375
2

= 5.13 cm
zt = (1.10 − 1.10) ⋅ 3.375 + 5.13 = 5.13 cm
For q n (1.20, 7.60, 3.50):
xt = 1.20 ⋅ 3.375 = 4.05 cm
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yt = (yibruh − ysbruh ) ⋅ Fcont (y, uh, 7) + (yibrlh − ysbrlh ) ⋅ Fcont (y, n, 7) + (y − ysbrn )
⋅ Fcont (y, n, 7)
= (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 + (7.60 − 6.70) ⋅ 3.180
= 21.48 cm
zt = (3.50 − 1.10) ⋅ 3.375 + 5.13 = 13.23 cm

Transformation of the trunk corner points:
For ptr (−4.00, 7.60, 0.10):
xt = −4.00 ⋅ 2.450 = −9.80 cm
yt = 21.48 cm
Zshift =

4.70 ⋅ 3.906 − 4.90 ⋅ 2.857
= 2.18 cm
2

zt = (0.10 − 0.10) ⋅ 2.857 + 2.18 = 2.18 cm
For q tr (4.00, 24.00, 4.90):
xt = 4.00 ⋅ 2.450 = 9.80 cm
yt = (yibruh − ysbruh ) ⋅ Fcont (y, uh, 7) + (yibrlh − ysbrlh ) ⋅ Fcont (y, n, 7) + (yibrn − ysbrn )
⋅ Fcont (y, n, 7) + (y − ysbrtr ) ⋅ Fcont (y, tr, 7)
= (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 + (7.60 − 6.70) ⋅ 3.180
+ (24.00 − 7.60) ⋅ 2.672 = 65.30 cm
zt = (4.90 − 0.10) ⋅ 2.857 + 2.18 = 15.89 cm

Transformation of the leg corner points:
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For plg (−2.80, 24.00, 1.10) and q lg (2.80, 43.20, 3.60):
The transformed x- and z-coordinates of the leg volume are the same as the transformed
x- and z-coordinates of the trunk. This was done because we have one leg volume in the
phantom. To prevent the leg volume lying outside the xz plane of the trunk when the
phantom is scaled to higher ages, we used the same scaling in the xz direction as for the
trunk. The length of the leg in the y direction is calculated using equation (4).
For plg (−2.8, 24.0, 1.1):
yt = 65.30 cm
For q lg (2.80, 43.2, 3.60):
yt = (yibruh − ysbruh ) ⋅ Fcont (y, uh, 7) + (yibrlh − ysbrlh ) ⋅ Fcont (y, n, 7) + (yibrn − ysbrn )
⋅ Fcont (y, n, 7) + (yibrtr − ysbrtr ) ⋅ Fcont (y, tr, 7) + (y − ysbrlg )
⋅ Fcont (y, lg, 7)
= (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 + (7.60 − 6.70) ⋅ 3.180
+ (24.00 − 7.60) ⋅ 2.672 + (43.20 − 24.00) ⋅ 2.894 = 120.01 cm

Transformation of the arm corner points:
For par (4.00, 8.00, 1.60):
On the x-axis, the arm starts at the same x-coordinate at which the trunk volume ends. Thus,
xt = 9.80 cm. On the y-axis, the volume starts at the same y-coordinate as the trunk.
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zt = (1.60 − 1.60) +

(4.70 − 0.00) ⋅ 3.906 − (3.20 − 1.60) ⋅ 3.475
= 6.40 cm
2

For q ar (5.60, 21.60, 3.20):
xt = 5.60 ⋅ 3.475 = 19.46 cm
yt = (yibruh − ysbruh ) ⋅ Fcont (y, uh, 7) + (yibrlh − ysbrlh ) ⋅ Fcont (y, n, 7) + (yibrn − ysbrn )
⋅ Fcont (y, n, 7) + (y − ysbrar ) ⋅ Fcont (y, ar, 7)
= (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 + (7.60 − 6.70) ⋅ 3.180
+ (21.60 − 8.00) ⋅ 2.985 = 62.08 cm
zt = (3.20 − 1.60) ⋅ 3.475 + 6.40 = 11.96 cm

Transformation of organ points:
The scaling and translation of organs is performed in the same way as the body regions in
which they are located. For example, we present here the scaling of one of the points of the
liver, which is present in the trunk region. The sample calculation for the point (-3.40, 14.30,
2.60) in the liver is shown below:
xt = −3.40 ⋅ 2.450 = −8.33 cm
yt = (3.80 − 1.00) ⋅ 3.357 + (6.70 − 3.80) ⋅ 3.180 + (7.60 − 6.70) ⋅ 3.180
+ (14.30 − 7.60) ⋅ 2.672 = 39.39 cm
zt = (2.60 − 0.10) ⋅ 2.857 +

4.70 ⋅ 3.906 − 4.90 ⋅ 2.857
= 9.32 cm
2

Hence, the transformed point of the liver is (-8.33, 39.39, 9.32).
Step 4: Reorient Phantom
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To model the phantom in the treatment planning system, we reorient our phantom to
head-first, supine (HFS). Thus, the y- and z-coordinates are reversed. This results in the
patient’s left to right orientation toward –x direction, superior to inferior orientation toward
–z direction, and anterior to posterior orientation toward +y direction. An example of the
calculated point of the liver in HFS orientation is presented below.
(-8.33, 39.39, 9.32)

y and z are flipped

(-8.33, 9.32, -39.39)

All organ points and body region corner points are reoriented in the same manner.
Steps 5, 6, and 7: Convert Body Regions and Organs to ROI/DICOM format and Plot
Phantom in RayStation
After the data are oriented in the HFS coordinate system, each body region is converted
from a collection of points to ROI format. Likewise, the collection of points representing an
organ is converted to ROI format. Next, the body regions and organs are plotted in
RayStation. RayStation allows users to export the phantom in DICOM format, which can be
imported for use in any other TPS.
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Appendix B: Scaling of any computational phantom using graphical user interface (GUI)
surface in RayStation TPS
We have developed a Graphical User Interface (GUI) application in RayStation TPS,
which can scale whole-body CT-based anatomy to any arbitrary ages using our ASF. While the
latest version of the GUI is discussed here, several modifications will be made soon to
accommodate the need for various phantoms and patient scans. The GUI has five tabs, each
of which is independent of one another. All of the scaling are performed in the ‘Patient
Import, and Scaling’ tab described below (shown in Figure 17).
The user first imports the phantom and then performs the scaling. In the import
panel, age, type of phantom (MDA, UC/NCI, and ICRP (when implemented)), and sex can be
specified to import phantoms from our structure template library in the TPS. This particular
step is not required if the user has already imported anatomy through DICOM import
functions. In the scaling panel, the user specifies the current age of the phantom and then
the final target age of the phantom. The user can further select the type of scaling from the
following options: MDA Main, 5th, 25th, 50th, 75th, 95th, and 99th percentile. The scaling
performed here is very fast as the time required to scale 5 body regions and 52 organs is
roughly 1.80 minutes. If we combine that time with the time required to import structures,
the total time is roughly 3 minutes.
The GUI is in the evolving stage and further modifications are undergoing in the
Howell Lab.
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Figure 17: GUI developed in the project to scale computational phantoms to arbitrary ages.
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